OA20027A - Isotretinoin oral-mucosal formulations and methods for using same. - Google Patents
Isotretinoin oral-mucosal formulations and methods for using same. Download PDFInfo
- Publication number
- OA20027A OA20027A OA1201900510 OA20027A OA 20027 A OA20027 A OA 20027A OA 1201900510 OA1201900510 OA 1201900510 OA 20027 A OA20027 A OA 20027A
- Authority
- OA
- OAPI
- Prior art keywords
- oral
- isotretinoin
- film
- inch
- mucoadhesive
- Prior art date
Links
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 title claims abstract description 128
- 229960005280 Isotretinoin Drugs 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims description 129
- 230000003232 mucoadhesive Effects 0.000 claims description 78
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 72
- 229920000642 polymer Polymers 0.000 claims description 52
- 238000004090 dissolution Methods 0.000 claims description 45
- 239000000853 adhesive Substances 0.000 claims description 38
- 230000001070 adhesive Effects 0.000 claims description 38
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 229920001577 copolymer Polymers 0.000 claims description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 208000004179 Oral Leukoplakia Diseases 0.000 claims description 6
- SYELZBGXAIXKHU-UHFFFAOYSA-N Lauryldimethylamine oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 94
- 229920002807 Thiomer Polymers 0.000 abstract description 28
- 201000010099 disease Diseases 0.000 abstract description 22
- 150000003839 salts Chemical class 0.000 abstract description 16
- 239000011780 sodium chloride Substances 0.000 abstract description 16
- 239000010408 film Substances 0.000 description 147
- 239000010410 layer Substances 0.000 description 116
- 238000009472 formulation Methods 0.000 description 57
- 239000003814 drug Substances 0.000 description 49
- 229940079593 drugs Drugs 0.000 description 49
- 239000002552 dosage form Substances 0.000 description 37
- -1 polyethylene Polymers 0.000 description 37
- 239000004014 plasticizer Substances 0.000 description 31
- 239000003963 antioxidant agent Substances 0.000 description 24
- 235000006708 antioxidants Nutrition 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000003078 antioxidant Effects 0.000 description 22
- 210000001519 tissues Anatomy 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 18
- 230000035492 administration Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 239000003086 colorant Substances 0.000 description 18
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 17
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 17
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- 239000002355 dual-layer Substances 0.000 description 14
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 13
- 239000002356 single layer Substances 0.000 description 12
- 210000003467 Cheek Anatomy 0.000 description 11
- 210000004400 Mucous Membrane Anatomy 0.000 description 11
- 210000004027 cells Anatomy 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 229920001888 polyacrylic acid Polymers 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 229920003134 Eudragit® polymer Polymers 0.000 description 8
- 210000000214 Mouth Anatomy 0.000 description 8
- 229950005134 Polycarbophil Drugs 0.000 description 8
- 229920000148 Polycarbophil calcium Polymers 0.000 description 8
- 239000002313 adhesive film Substances 0.000 description 8
- 239000003607 modifier Substances 0.000 description 8
- 231100000017 mucous membrane irritation Toxicity 0.000 description 8
- 230000035899 viability Effects 0.000 description 8
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 7
- 229920003156 Eudragit® RL PO Polymers 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000010409 thin film Substances 0.000 description 7
- 229960003438 Aspartame Drugs 0.000 description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 6
- 108010011485 Aspartame Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- VILCJCGEZXAXTO-UHFFFAOYSA-N Triethylenetetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 6
- 239000000605 aspartame Substances 0.000 description 6
- 235000010357 aspartame Nutrition 0.000 description 6
- 239000000227 bioadhesive Substances 0.000 description 6
- 238000005266 casting Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000011888 foil Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 229920000193 polymethacrylate Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000004408 titanium dioxide Substances 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000002200 Mouth Mucosa Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003628 erosive Effects 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 5
- 235000019477 peppermint oil Nutrition 0.000 description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N ARBUTIN Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 241001366896 Ape Aime-Itapua virus Species 0.000 description 4
- ZIUSSTSXXLLKKK-HWUZOJPISA-N Curcumin Natural products C1=C(O)C(OC)=CC(\C=C\C(\O)=C/C(=O)/C=C/C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-HWUZOJPISA-N 0.000 description 4
- 229960002433 Cysteine Drugs 0.000 description 4
- ACTRVOBWPAIOHC-XIXRPRMCSA-N Dimercaptosuccinic acid Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 4
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 4
- 229920003083 Kollidon® VA64 Polymers 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229940075579 Propyl Gallate Drugs 0.000 description 4
- 229960001124 Trientine Drugs 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 229940046009 Vitamin E Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 4
- POXPUHKJGLHZEM-VIPPSAFOSA-L disodium;(5E)-5-[(2-methoxy-5-methyl-4-sulfonatophenyl)hydrazinylidene]-6-oxonaphthalene-2-sulfonate Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N\N=C\1C2=CC=C(S([O-])(=O)=O)C=C2C=CC/1=O POXPUHKJGLHZEM-VIPPSAFOSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003522 irritant Effects 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 235000010388 propyl gallate Nutrition 0.000 description 4
- 239000000473 propyl gallate Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 150000003712 vitamin E derivatives Chemical class 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 3
- 239000004698 Polyethylene (PE) Substances 0.000 description 3
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 3
- 229920003082 Povidone K 90 Polymers 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229960001639 penicillamine Drugs 0.000 description 3
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- BAQAVOSOZGMPRM-JVFSCRHWSA-N (2R,3R,4R,5R,6R)-2-[(2S,3R,4R,5R)-2,5-bis(chloromethyl)-3,4-dihydroxyoxolan-2-yl]oxy-5-chloro-6-(hydroxymethyl)oxane-3,4-diol Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@]1(CCl)[C@H](O)[C@@H](O)[C@H](CCl)O1 BAQAVOSOZGMPRM-JVFSCRHWSA-N 0.000 description 2
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 2
- BHDQYOCGJKADDC-UHFFFAOYSA-N 3-tert-butyl-2-methoxyphenol Chemical class COC1=C(O)C=CC=C1C(C)(C)C BHDQYOCGJKADDC-UHFFFAOYSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 2
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 2
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 2
- 229960000271 Arbutin Drugs 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229940109262 Curcumin Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N Dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 2
- 229960001051 Dimercaprol Drugs 0.000 description 2
- 229960001484 Edetic Acid Drugs 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 229960001031 Glucose Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 Glutathione Drugs 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- 235000016247 Mentha requienii Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 229940041616 Menthol Drugs 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- PMRYVIKBURPHAH-UHFFFAOYSA-N Methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 2
- 229940042048 Methimazole Drugs 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 2
- DSRJIHMZAQEUJV-UHFFFAOYSA-N N,N'-bis(cyclohexylideneamino)oxamide Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 2
- IYRGXJIJGHOCFS-UHFFFAOYSA-N Neocuproine Chemical compound C1=C(C)N=C2C3=NC(C)=CC=C3C=CC2=C1 IYRGXJIJGHOCFS-UHFFFAOYSA-N 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229960001285 Quercetin Drugs 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Quinoform Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 2
- 210000003296 Saliva Anatomy 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- UEDUENGHJMELGK-VESORUSYSA-N Stevioside Natural products O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 UEDUENGHJMELGK-VESORUSYSA-N 0.000 description 2
- 229960005346 Succimer Drugs 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- VXMKYRQZQXVKGB-CWWHNZPOSA-N Tannin Chemical compound O([C@H]1[C@H]([C@@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)O[C@H]([C@H]2O)O1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 VXMKYRQZQXVKGB-CWWHNZPOSA-N 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N Vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229940071097 ascorbyl phosphate Drugs 0.000 description 2
- 235000006682 bigleaf mint Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960005228 clioquinol Drugs 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M ferulate Chemical compound COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- 229940114123 ferulate Drugs 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000006679 mint Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229930002344 quercetin Natural products 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 229940001474 sodium thiosulfate Drugs 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 229960002178 thiamazole Drugs 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 229930003799 tocopherols Natural products 0.000 description 2
- 231100000730 tolerability Toxicity 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GGCUJPCCTQNTJF-NAXRMXIQSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C GGCUJPCCTQNTJF-NAXRMXIQSA-N 0.000 description 1
- AYIYPHDKKVWZKI-LJTMIZJLSA-N (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol;piperazine Chemical compound C1CNCCN1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO AYIYPHDKKVWZKI-LJTMIZJLSA-N 0.000 description 1
- ILRKKHJEINIICQ-UFTZEXNXSA-N (2S,3S,4S,5R,6R)-6-[(3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carb Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](OC1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-UFTZEXNXSA-N 0.000 description 1
- GGCUJPCCTQNTJF-FAOQNJJDSA-N (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)CCC1(C)C GGCUJPCCTQNTJF-FAOQNJJDSA-N 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229960004998 Acesulfame potassium Drugs 0.000 description 1
- 229940008309 Acetone / Ethanol Drugs 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 240000001101 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 240000002254 Ananas comosus Species 0.000 description 1
- 235000007639 Anthemis cotula Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 210000000941 Bile Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 240000001358 Bromus mango Species 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- SXVBHNXTPNLOKR-FCLWLKJISA-L Calcium alginate Chemical compound [Ca+2].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O SXVBHNXTPNLOKR-FCLWLKJISA-L 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 description 1
- 240000000613 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000002268 Citrus limon Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 240000007170 Cocos nucifera Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FLKPEMZONWLCSK-UHFFFAOYSA-N Diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 240000000716 Durio zibethinus Species 0.000 description 1
- 235000006025 Durio zibethinus Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 229920003149 Eudragit® E 100 Polymers 0.000 description 1
- 229940051147 FD&C yellow no. 6 Drugs 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MYOOOWEVSA-N Glycyrrhizic acid Natural products O=C(O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1 LPLVUJXQOOQHMX-MYOOOWEVSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000004969 Inflammatory Cells Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229960001375 Lactose Drugs 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 240000007119 Malus pumila Species 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 240000000744 Mentha spicata Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000001983 Palate, Hard Anatomy 0.000 description 1
- 210000001584 Palate, Soft Anatomy 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002571 Polyethylene Glycol 4500 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229940069328 Povidone Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 240000002799 Prunus avium Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229960001462 Sodium Cyclamate Drugs 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960004793 Sucrose Drugs 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000005147 Syzygium aromaticum Species 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 240000000280 Theobroma cacao Species 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000036201 Tissue concentration Effects 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L Zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000002354 carica papaya Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000001544 chamomile Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000009754 grape Nutrition 0.000 description 1
- 235000012333 grape Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M potassium;6-methyl-2,2-dioxooxathiazin-4-olate Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000001062 red colorant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229920003179 starch-based polymer Polymers 0.000 description 1
- 239000004628 starch-based polymer Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 229910001929 titanium oxide Inorganic materials 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 229940117960 vanillin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 201000006083 xeroderma pigmentosum Diseases 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Abstract
Disclosed herein, in part, is a pharmaceutical formulation comprising isotretinoin or a pharmaceutically acceptable salt thereof, and a mucoadhesive polymer. A method of treating a mucosal disease comprising administering a disclosed pharmaceutical formulation to a subject in need thereof is also provided herein.
Description
BACKGROUND
Isotretinoin is 13-cis-retinoic acid and is a dérivative of vitamin A. Isotretinoin was originally developed and approved for the treatment of acné. However, it has been extensively studied for use in the treatment of various diseases, including neuroblastoma, récurrent prostate cancer, leukemia, high-grade glioma, head and neck cancers and multiple myeloma, certain dermatological disorders such as xeroderma pigmentosum, gram-negative folliculitis, récalcitrant rosacea, pyoderma faciale, generalized lichen planus, psoriasis, cutaneous lupus erythematosus, acné fulminans, and squamous cell carcinoma, as well as mucosal diseases. Isotretinoin was initially developed as a capsule, and subsequently gel and cream formulations were also developed.
Mucoadhesive films hâve emerged as advanced dosage fonns that provide a useful alternative to traditional tablets, capsules, soft gels and liquids. Mucoadhesive films are thin film strips, squares or dises containing an active pharmaceutical ingrédient (API) and typically designed for intra-oral administration, with the patient placing the strip on or under the tongue (lingual or sublingual) or along the inside of the cheek (buccal). As the thin film dissolves/erodes, the drug is released and delivered into the blood stream either intragastrically, buccally or sublingually.
Mucoadhesive films can generally be classified into two categories: fast dissolving/eroding films and slow dissolving/eroding films. Fast dissolving/eroding films, which typically comprise polymers of high water solubility, are designed as a convenient form for lingual administration and gastro-intestinal (GI) tract absorption. The active ingrédients are incorporated in the film matrix, which dissolves rapidly on the tongue and is then swallowed into the GI tract for absorption. No water is required, making this dosage form convenient for the consumer or patient. This type of dosage form may be particularly useful for pédiatrie and gériatrie patients, and patients with difficulty in swallowing tablets. The second class of bioadhesive films is designed for controlled or sustained release of API. These films contain at least a slow dissolving or eroding polymer. Slow dissolving/eroding films are mainly designed for systemic administration via the interior lining of the cheek (buccal mucosa) or for local treatment.
Ail tablet dosage forms, soft gels and liquid formulations primarily enter the blood stream via the gastrointestinal tract, which subjects the drug to dégradation from stomach acid, bile, digestive enzymes and other first pass effects. As a resuit, such formulations often require higher doses and generally hâve a delayed onset of action. Non-systemic buccal and sublingual thin film drug delivery can avoid these issues and yield quicker onsets of action at lower doses.
However, it remains a challenge to deliver an active agent buccally while minimizing systemic interaction and buccal irritation. Further, there remains a pressing need for treatment of oral premalignant lésions and other oral cavity or oropharynx disorders to assist in preventing progression to malignant lésions. Currently there are no approved pharmacologie treatments for such oral premalignant lésions (OPLs).
SUMMARY
In one aspect, provided herein is a pharmaceutically acceptable film for mucosal delivery of isotretinoin. Contemplated films include isotretinoin and mucosal adhesive polymer such as described herein. For example, a mucosal adhesive pharmaceutical film is provided that comprises: a mucoadhesive layer comprising about 0.05% to about 0.5% w/w isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive, hydrophilic biocompatible polymer; and optionally an occlusive backing layer.
In some embodiments, contemplated herein is a composition having a mucoadhesive layer (e.g. a mucoadhesive hydrophilic biocompatible layer) or composition that comprises a vinylpyrrolidone-vinyl acetate co-polymer and/or a polyvinylpyrrolidone (PVP). In some embodiments, a mucoadhesive hydrophilic biocompatible polymer is selected from the group consisting of a vinylpyrrolidone-vinyl acetate co-polymer, a PVP, a carbopol, a polycarbophil, a xanthan gum, an alginate or any pharmaceutically acceptable sait thereof, a chitosan, a polyethylene oxide, a polyvinyl alcohol, a cellulose polymer, and combinations thereof. For example, provided herein is a film having a mucoadhesive layer that includes a PVP has a weight average molecular weight of about 70,000 g/mol to about 1,600,000 g/mol, or e.g., a K value of
80, 85, 90 or 95, for example 90. Contemplated films may include a vinylpyrrolidone-vinyl acetate co-polymer having a weight average molecular weight of about 45,000 g/mol to about 70,000 g/mol.
A contemplated mucoadhesive layer may include about 0.1% w/w, about 0.2% w/w, about 0.3% w/w, about 0.4% w/w, or about 0.5% w/w isotretinoin, for example, about 0.1%w/w to about 1% w/w.
In some embodiments, a mucosal adhesive pharmaceutical film includes the occlusive backing layer, wherein the occlusive backing layer is substantially free of isotretinoin. A contemplated occlusive backing layer can include one or more méthacrylate co-polymers. For example, an ingestible, occlusive backing layer, if présent, can include a polymer selected from the group consisting of poly(methacrylic acid-co-ethylacrylate) 1:1, poly(ethyl acrylate-comethyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2 and combinations thereof.
In some embodiments, the mucoadhesive layer and/or the occlusive backing layer further comprises a plasticizer. In some embodiments, the plasticizer is propylene glycol and/or a PEG. In some embodiments, the PEG has a weight average molecular weight of about 380 g/mol to about 420 g/mol. In some embodiments, the PEG is PEG 400.
A contemplated mucoadhesive layer may further comprise at least one of: an opacifying agent, a colorant, and/or an antioxidant. In some embodiments, the opacifying agent is titanium oxide. In some embodiments, the antioxidant is butylated hydroxytoluene (BHT). In some embodiments, the mucoadhesive layer further comprises a colorant and the occlusive backing layer comprises a colorant different than that in the mucoadhesive layer.
In one aspect, provided herein is a multilayered pharmaceutical formulation comprising: (1) a first layer comprising isotretinoin or a pharmaceutically acceptable sait thereof and a mucoadhesive polymer; and (2) a second layer comprising an ingestible backing film. In some embodiments, the second layer comprises a methacrylate-based co-polymer.
For example, provided herein is a pharmaceutically acceptable film wherein more than 85% of the isotretinoin is released within 60 minutes, within 20 minutes or even within 15 minutes using a USP 3 and 7 dissolution apparatus. For example, contemplated herein is a film that may be applied to a patient’s mucosal région (e.g., mouth, throat) for 15 minutes, for example daily.
In one aspect, provided herein is a mucosal adhesive pharmaceutical film comprising: a mucoadhesive layer comprising about 0.1% w/w, about 0.2% w/w or about 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 12% w/w to about 15% w/w vinylpyrrolidone-vinyl acetate copolymer, about 53% w/w to about 57% w/w PVP, about 16% w/w to about 19% w/w PEG 400 and about 4% w/w to about 6% w/w propylene glycol; and an occlusive backing layer.
In some embodiments, the occlusive backing layer comprising about 40% w/w to about 45% w/w poly(methacrylic acid-co-ethylacrylate) 1:1, about 25% w/w to about 30% w/w poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2, about 13% w/w to about 16% w/w PEG 400 and about 4% w/w to about 6% w/w propylene glycol.
In one aspect, provided herein is a kit for suitable storage of an isotretinoin oral film comprising: a multilayered laminate pouch suitable for packaging of any one of the mucosal adhesive pharmaceutical films or pharmaceutical formulations provided herein, and any one of the mucosal adhesive phannaceutical films or pharmaceutical formulations provided herein provided herein. In some embodiments, the multilayered laminate pouch comprises polyester and polyethylene film laminate. In some embodiments, the multilayered laminate pouch further comprises aluminum.
In one aspect, provided herein is a method of treating an oral premalignant lésion in a patient in need thereof comprising mucosally applying any of the films or compositions of any one of the provided herein to the patient, thereby administering an effective amount of the isotretinoin to the patient. In some embodiments, the oral premalignant lésion is oral leukoplakia or oral erythroplakia.
In some embodiments, mucosally applying comprises applying the mucoadhesive layer to the lésion on a mucosa of the mouth of the patient. In some embodiments, one or more lésions are treated comprising applying one or more films or compositions.
In one aspect, provided herein is a method of treating an oral premalignant lésion in a patient in need thereof comprising mucosally applying an orally adhesive film comprising about 0.1 to about 0.3 w/w of isotretinoin to the oral premalignant lésion for about 30 minutes once daily.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows that the drug was released in about 15-20 minutes of dissolution in in vivo drug release studies of formulation B (see Example 2).
Figure 2 shows the cytotoxicity in 2D cultured oral épithélial cells of different concentrations of isotretinoin.
Figure 3 shows the relative viability of 3D cultured gingival cells after 4 hours in the presence of 0.1%, 0.2% and 0.3% isotretinoin.
Figure 4 shows the isotretinoin release profiles for three oral mucoadhesive films comprising 0.1% w/w, 0.2% w/w and 0.3% w/w isotretinoin.
DETAILED DESCRIPTION
The présent disclosure provides, in part, pharmaceutical formulations comprising isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive polymer. The pharmaceutical formulations of the présent disclosure are, in part, useful for the treatment of mucosal diseases, for example, oral leukoplakia. The dosage form of a disclosed pharmaceutical formulation may be a mucosal adhesive pharmaceutical film having isotretinoin, which may, for example, achieve substantially one directional drug release (e.g., absorption and/or mucosal perméation) to achieve effective local delivery to the intended tissue, such as an oral premalignant lésion and, for example, may avoid systemic uptake and/or déposition in adjacent tissues. Such provided formulations (e.g., films) may hâve minimal skin/mucosal irritation (or no irritation) when administered, and/or may provide minimal ( or no) systemic availability of the drug.
Définitions
As used herein, the tenu “about” means approximately, in the région of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10%.
“Individual,” “patient,” and “subject” are used interchangeably and include any animal, including mammals, e.g., mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, including humans.
“A patient in need,” as used herein, refers to a patient suffering from any of the symptoms or manifestations of a mucosal disease, a patient who may suffer from any ofthe symptoms or manifestations of a mucosal disease, or any patient who might benefit from a method of the disclosure for treating a mucosal disease.
The tenus treat,” treatment,” treating and the like are used herein to generally mean obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a mucosal disease or symptom thereof and/or may be therapeutic in tenus of partially or completely curing a mucosal disease and/or adverse effect attributed to a mucosal disease.
“Isotretinoin” as used herein refers to isotretinoin in the form of a free acid or its pharmaceutically acceptable salts. Isotretinoin may be referred to as 13-cis-retinoic acid or (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-l-en-l-yl)nona-2,4,6,8-tetraenoic acid. Tretinoin (all-trans retinoic acid) and isotretinoin are géométrie isomers and show réversible interconversion in vivo. The administration of one isomer can give rise to another. Other major métabolites of isotretinoin, such as 4-oxo-isotretinoin and its geometrical isomer 4-oxo-tretinoin, are also contemplated in the term “isotretinoin.” “Pharmaceutically acceptable” includes molecular entities and formulations that do not produce an adverse, allergie or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, préparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA Office of Biologics standards.
The pharmaceutical formulations of the disclosure can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animais (e.g., dogs, cats, and the like), farm animais (e.g., cows, sheep, pigs, horses, and the like) and laboratory animais (e.g., rats, mice, guinea pigs, and the like). The mammal treated in the methods of the disclosure is desirably a mammal in which treatment of a mucosal disease is desired.
The tenu “non-systemic” or “non-systemic administration” as used herein refers to an agent that has been administered locally and has only a local and/or topical effect to the affected area, e.g., oral mucosa. This includes the application of the pharmaceutical formulation described herein extemally to the epidermis.
The tenu “local administration” as used herein refers to the administration of a pharmaceutical agent to or to the vicinity of a mucosa or a submucosa location in a subject by a non-systemic route.
The term “mucoadhesive polymer” as used herein refers to a polymer adhesive to mucus or mucous membrane. Mucoadhesive polymers are in general predominantly hydrophilic bioadhesive polymers. For example, a mucoadhesive polymer may be polyacrylic acids, xanthan gum, polyvinylpyrrolidone (PVP) (e.g., Kollidon 90 and Kollidon VA-64), carrageenan, pectin, sodium carboxymethylcellulose, alginate and pharmaceutically acceptable salts thereof, chitosan, polyvinyl alcohol, polyethylene oxide, or mixtures thereof. Such polyacrylic acids include, for example, cross-linked poly(acrylic acid) [e.g., carbopol] and polycarbophil. For example, polycarbophil may be Noveon, e.g., Noveon AAI.
The term “plasticizer” as used herein refers to a substance added to a material to produce or promote plasticity and flexibility and to reduce brittleness. The plasticizer can hâve surfactant properties such that it can act as a release modifier. For example, non-ionic détergents such as Brij 58 (polyoxyethylene (20) cetyl ether), and the like, can be used. Plasticizers impart flexibility to the dosage forms and can affect the release profile of the bioactive agent. For example, a plasticizer may be propylene glycol, polyethylene glycol (e.g., PEG 300, PEG 400, PEG 600, PEG 1000, PEG 1450, PEG 1500, PEG 3350, PEG 4500, PEG 8000), triacetin, triethyl citrate, castor oil, diethyl phthalate, or glycerin.
The term “antioxidant’’ as used herein refers to a molécule that inhibits the oxidation of other molécules. For example, an antioxidant may be, but not limited to, butylated hydroxytoluene, butylated hydroxyanisole, N-acetylcysteine, ascorbyl palmitate, 2,5dihydroxybenzoic acid, propyl gallate, edetic acid, sodium edetate, L-cysteine, sodium metabisulfite, glutathione, cysteine, ascorbic acid and salts thereof, captopril, Na-ascorbate, Na2EDTA, Na2-EDTA-Ca, methimazole, quercetin, arbutin, aloesin, N-acetylglucoseamine, atocopheryl ferulate, MAP (Mg ascorbyl phosphate), sodium benzoate, L-phenylalanine, DMSA (succimer), DP A (D-penicillamine), trientine-HCl, dimercaprol, clioquinol, sodium thiosulfate, TETA (triethylenetetramine), ΤΕΡΑ (tetraethylenepentamine), curcumin, neocuproine, tannin, cuprizone, sodium hydrogen sulfite, lipoic acid, Trx-mimetic compounds (e.g., CB3, CB4, CB6), AD4, AD6, AD7, Vitamin E, di-tert-butyl methyl phénols, tert-butyl-methoxyphenols, polyphenols, tocopherols ubiquinones, or caffeic acid.
Pharmaceutical Formulations and Dosage Forms
The présent disclosure relates, in part, to pharmaceutical formulations comprising isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive polymer. In some embodiments, the pharmaceutical formulation is a mucosal adhesive pharmaceutical film. The pharmaceutical formulations of the présent disclosure can be useful for the treatment of various mucosal diseases. In certain embodiments, the mucosal disease is an oral premalignant lésion. In some embodiments, the oral premalignant lésion is oral leukoplakia or oral erythroplakia.
In an embodiment, the mucosal adhesive pharmaceutical film comprises a mucoadhesive layer. In some embodiments, the mucoadhesive layer comprises a mucoadhesive polymer. In some embodiments, the mucosal adhesive pharmaceutical film optionally comprises an occlusive backing layer.
In an embodiment, the mucoadhesive polymer is hydrophilic, water-soluble, waterdisintegrable and/or water-erodible. In an embodiment, the mucoadhesive polymer is a waterswellable polymer. In some embodiments, the mucoadhesive polymer is a mucoadhesive, hydrophilic biocompatible polymer.
In an embodiment, the mucoadhesive polymer is a polymer selected from the group consisting of Carbopol®, polycarbophil, xanthan gum, and polyvinylpyrrolidone (PVP). In an embodiment, the mucoadhesive polymer is selected from the group consisting of a chitosan, an alginate (e.g., sodium alginate, calcium alginate) and a high weight average molecular weight polyethylene oxide (PEO) (e.g., PolyOx N750, 1105, WSR-301).
In an embodiment, the mucoadhesive polymer is polycarbophil. e.g., Noveon AAI.
In an embodiment, the mucoadhesive polymer is a polyvinylpyrrolidone (PVP), e.g., povidone (e.g., Kollidon® 90).
In sonie embodiments, the P VP has a weight average molecular weight from about 1,000,000 g/mol to about 1,500,000 g/mol. In some embodiments, the PVP has a K value of 90.
In an embodiment, the mucoadhesive polymer is a polyvinyl alcohol (PVA) (e.g., Exceval, Selvol). In an embodiment, the mucoadhesive polymer is a polyethylene oxide (PEO). In some embodiments, the polyethylene oxide is a low molecular weight PEO (e.g., PolyOx N10). In an embodiment, the mucoadhesive polymer is a starch-based polymer (e.g., Lycoat).
In some embodiments, the mucoadhesive layer comprises a vinylpyrrolidone-vinyl acetate co-polymer and PVP. In some embodiments, the vinylpyrrolidone-vinyl acetate copolymer has a weight average molecular weight of about 45,000 g/mol to about 70,000 g/mol.
In some embodiments, a first mucoadhesive polymer is présent in the pharmaceutical formulation at a concentration of about 50% w/w, about 51% w/w, about 52% w/w, about 53% w/w, about 54% w/w, about 55% w/w, about 56% w/w, about 57% w/w, about 58% w/w, about 59% w/w, or about 60% w/w. In some embodiments, the mucoadhesive polymer is présent in the pharmaceutical formulation at a concentration from about 50% w/w to about 60% w/w, about 51% w/w to about 60% w/w, about 52% w/w to about 60% w/w, about 53% w/w to about 60% w/w, about 54% w/w to about 60% w/w, about 55% w/w to about 60% w/w, about 56% w/w to about 60% w/w, about 57% w/w to about 60% w/w, about 58% w/w to about 60% w/w, about 59% w/w to about 60% w/w, about 50% w/w to about 59% w/w, about 50% w/w to about 58% w/w, about 50% w/w to about 57% w/w, about 50% w/w to about 56% w/w, about 50% w/w to about 55% w/w, about 50% w/w to about 54% w/w, about 50% w/w to about 53% w/w, about 50% w/w to about 52% w/w, about 50% w/w to about 51% w/w, about 51% w/w to about 52% w/w, 51% w/w to about 53% w/w, 51% w/w to about 54% w/w, 51% w/w to about 55% w/w, 51% w/w to about 56% w/w, 51% w/w to about 57% w/w, 51% w/w to about 58% w/w, 51% w/w to about 59% w/w, 52% w/w to about 53% w/w, 52% w/w to about 54% w/w, 52% w/w to about 55% w/w, 52% w/w to about 56% w/w, 52% w/w to about 57% w/w, 52% w/w to about 58% w/w, 52% w/w to about 59% w/w, 53% w/w to about 54% w/w, 53% w/w to about 55% w/w, 53% w/w to about 56% w/w, 53% w/w to about 57% w/w, 53% w/w to about 58% w/w, 53% w/w to about 59% w/w, 54% w/w to about 55% w/w, 54% w/w to about 56% w/w, 54% w/w to about 57% w/w, 54% w/w to about 58% w/w, 54% w/w to about 59% w/w, 55% w/w to about 56% w/w, 55% w/w to about 57% w/w, 55% w/w to about 58% w/w, 55% w/w to about 59% w/w, 56% w/w to about 57% w/w, 56% w/w to about 58% w/w, 56% w/w to about 59% w/w, 57% w/w to about 58% w/w, 57% w/w to about 59% w/w, or 58% w/w to about 59% w/w.
In some embodiments, the first mucoadhesive polymer is P VP.
In an embodiment, the pharmaceutical formulation comprises a second mucoadhesive polymer. In some embodiments, the second mucoadhesive polymer is présent in the pharmaceutical formulation at a concentration of about 10% w/w, about 11% w/w, about 12% w/w, about 13% w/w, about 14% w/w, about 15% w/w, about 16% w/w, about 17% w/w, about 18% w/w, about 19% w/w, or about 20% w/w. In some embodiments, the second mucoadhesive polymer is présent in the pharmaceutical formulation at a concentration from 10% w/w to about 20% w/w, about 11% w/w to about 20% w/w, about 12% w/w to about 20% w/w, about 13% w/w to about 20% w/w, about 14% w/w to about 20% w/w, about 15% w/w to about 20% w/w, about 16% w/w to about 20% w/w, about 17% w/w to about 20% w/w, about 18% w/w to about 20% w/w, about 19% w/w to about 20% w/w, about 10% w/w to about 19% w/w, about 10% w/w to about 18% w/w, about 10% w/w to about 17% w/w, about 10% w/w to about 16% w/w, about 10% w/w to about 15% w/w, about 10% w/w to about 14% w/w, about 10% w/w to about 13% w/w, about 10% w/w to about 12% w/w, about 10% w/w to about 11% w/w, about 11% w/w to about 12% w/w, 11% w/w to about 13% w/w, 11% w/w to about 14% w/w, 11% w/w to about 15% w/w, 11% w/w to about 16% w/w, 11% w/w to about 17% w/w, 11% w/w to about 18% w/w, 11% w/w to about 19% w/w, 12% w/w to about 13% w/w, 12% w/w to about 14% w/w, 12% w/w to about 15% w/w, 12% w/w to about 16% w/w, 12% w/w to about 17% w/w, 12% w/w to about 18% w/w, 12% w/w to about 19% w/w, 13% w/w to about 14% w/w, 13% w/w to about 15% w/w, 13% w/w to about 16% w/w, 13% w/w to about 17% w/w, 13% w/w to about 18% w/w, 13% w/w to about 19% w/w, 14% w/w to about 15% w/w, 14% w/w to about 16% w/w, 14% w/w to about 17% w/w, 14% w/w to about 18% w/w, 14% w/w to about 19% w/w, 15% w/w to about 16% w/w, 15% w/w to about 17% w/w, 15% w/w to about 18% w/w, 15% w/w to about 19% w/w, 16% w/w to about 17% w/w, 16% w/w to about 18% w/w, 16% w/w to about 19% w/w, 17% w/w to about 18% w/w, 17% w/w to about 19% w/w, or 18% w/w to about 19% w/w. In some embodiments, the second mucoadhesive polymer is a vinylpyrrolidone-vinyl acetate co-polymer.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in the pharmaceutical formulation in a concentration of at least about 0.05% w/w, at least about 0.1% w/w, at least about 0.15% w/w, at least about 0.2% w/w, at least about 0.25% w/w, at least about 0.3% w/w, at least about 0.35% w/w, at least about 0.4% w/w, at least about 0.45% w/w, or at least about 0.5% w/w. In some embodiments, isotretinoin or a pharmaceutically acceptable sait thereof is présent in the pharmaceutical formulation in a concentration from about 0.05% w/w to about 0.5% w/w, about 0.1% w/w to about 0.5% w/w, about 0.15% w/w to about 0.5% w/w, about 0.2% w/w to about 0.5% w/w, about 0.25% w/w to about 0.5% w/w, about 0.3% w/w to about 0.5% w/w, about 0.35% w/w to about 0.5% w/w, least about 0.40% w/w to least about 0.5% w/w, about 0.45% w/w to about 0.5% w/w, about 0.05% w/w about 0.45% w/w, about 0.05% w/w to about 0.4% w/w, about 0.05% w/w to about 0.35% w/w, about 0.05% w/w to about 0.3% w/w, about 0.05% w/w to about 0.25% w/w, about 0.05% w/w to about 0.2% w/w, about 0.05% w/w to about 0.15% w/w, about 0.05% w/w to about 0.1% w/w, about 0.1% w/w to about 0.45%, about 0.1% w/w to about 0.4%, about 0.1% w/w to about 0.35%, about 0.1% w/w to about 0.3%, about 0.1% w/w to about 0.25%, about 0.1% w/w to about 0.2%, about 0.1% w/w to about 0.15%, about 0.15% w/w to about 0.45%, about 0.15% w/w to about 0.4%, about 0.15% w/w to about 0.35%, about 0.15% w/w to about 0.3%, about 0.15% w/w to about 0.25%, about 0.15% w/w to about 0.2%, about 0.2% w/w to about 0.45%, about 0.2% w/w to about 0.4%, about 0.2% w/w to about 0.35%, about 0.2% w/w to about 0.3%, about 0.2% w/w to about 0.25%, about 0.25% w/w to about 0.45%, about 0.25% w/w to about 0.4%, about 0.25% w/w to about 0.35%, about 0.25% w/w to about 0.3%, about 0.3% w/w to about 0.45%, about 0.3% w/w to about 0.4%, about 0.3% w/w to about 0.35%, about 0.35% w/w to about 0.45%, about 0.35% w/w to about 0.4%, or about 0.4% w/w to about 0.45%.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration from about 0.1% w/w to about 0.3% w/w.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration from about 0.2% w/w to about 0.4% w/w.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration from about 0.05% to about 0.5% w/w or from about 0.1% to about 0.4% w/w.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration of about 0.1 % w/w.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration of about 0.2% w/w.
In an embodiment, isotretinoin or a pharmaceutically acceptable sait thereof is présent in a concentration of about 0.3% w/w.
In one aspect, provided herein is a mucosal adhesive phannaceutical film comprising: a mucoadhesive layer comprising about 0.05% to about 0.5% w/w isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive, hydrophilic biocompatible polymer; and optionally an occlusive backing layer.
In an embodiment, the phannaceutical formulation further comprises a cellulose polymer.
In an embodiment, the cellulose polymer is a hydroxyalkyl cellulose polymer selected from the group consisting of hydroxypropylmethyl cellulose (HPMC), hydroxyethylpropyl cellulose (HEPC), hydroxybutylmethyl cellulose (HBMC), hydroxylpropyl cellulose (HPC), hydroxylethyl cellulose (HEC) and carboxymethyl cellulose (CMC).
In an embodiment, the cellulose polymer is HPMC, for example, HPMC E5 (e.g., 2hydroxypropyl methyl ether cellulose).
In an embodiment, the pharmaceutical formulation/ the mucoadhesive layer fùrther comprises a plasticizer. In some embodiments, the pharmaceutical formulation/the mucoadhesive layer comprises 1, 2, 3, 4, or 5 plasticizers. In some embodiments, the total concentration of plasticizer in the pharmaceutical fonnulation/the mucoadhesive layer is about 5% w/w, about 7.5%, about 10% w/w, about 12.5% w/w, about 15% w/w, about 17.5% w/w, about 20% w/w, about 22.5% w/w, about 25% w/w, about 27.5% w/w, or about 30% w/w. In some embodiments, the total concentration of plasticizer in the pharmaceutical formulation/the mucoadhesive layer is from about 5% w/w to about 30% w/w, about 5% w/w to about 25% w/w, about 5% w/w to about 20% w/w, about 5% w/w to about 15% w/w, about 5% w/w to about 10% w/w, about 10% w/w to about 30% w/w, about 15% w/w to about 30% w/w, about 20% w/w to about 30% w/w, about 25% w/w to about 30% w/w, about 10% w/w to about 25% w/w, about 10% w/w to about 20% w/w, about 10% w/w to about 15% w/w, about 15% w/w to about 25% w/w, about 15% w/w to about 20% w/w, or about 20% w/w to about 25% w/w. In some embodiments, the pharmaceutical formulation/the mucoadhesive layer comprises propylene glycol and/or a PEG. In some embodiments, the PEG is PEG 400. In some embodiments, the PEG has a weight average molecular weight of about 380 g/mol to about 420 g/mol. In some embodiments, propylene glycol is présent in the pharmaceutical formulation/the mucoadhesive layer at a concentration of about 4.5% w/w, about 4.6% w/w, about 4.7% w/w, about 4.8% w/w, about 4.9% w/w, about 5.0% w/w, about 5.1% w/w, about 5.2% w/w, about 5.3% w/w, about 5.4% w/w, or about 5.5% w/w. In some embodiments, propylene glycol is présent in the pharmaceutical formulation/the mucoadhesive layer at a concentration from about 4.5% w/w to about 4.7% w/w, 4.5% w/w to about 4.9% w/w, 4.5% w/w to about 5.1% w/w, 4.5% w/w to about 5.3% w/w, 4.5% w/w to about 5.5% w/w, 4.7% w/w to about 4.9% w/w, about 4.7% w/w to about 5.1% w/w, about 4.7% w/w to about 5.3% w/w, about 4.7% w/w to about 5.5% w/w, about 4.9% w/w to about 5.1% w/w, about 4.9% w/w to about 5.3% w/w, about 4.9% w/w to about 5.5% w/w, 5.1% w/w to about 5.3% w/w, about 5.1% w/w to about 5.5% w/w, about 5.3% w/w to about 5.5% w/w, 4.6% w/w to about 4.8% w/w, 4.6% w/w to about 5.0% w/w, 4.6% w/w to about 5.2% w/w, 4.6% w/w to about 5.4% w/w, 4.8% w/w to about 5.0% w/w, about 4.8% w/w to about 5.2% w/w, about 4.8% w/w to about 5.4% w/w, about 5.0% w/w to about 5.2% w/w, about 5.0% w/w to about 5.4% w/w, 5.2% w/w to about 5.4% w/w, about 5.2% w/w to about 5.4% w/w, about 4.5% to about 5.5%, about 4.5% w/w to about 5.2, about 4.5% w/w to about 4.9% w/w, about 4.8% to about 5.5%, about 5.1% to about 5.5%, about 4.5% w/w to about 5.0% w/w, or about 5.0% w/w to about 5.5% w/w. In some embodiments, PEG 400 is présent in the pharmaceutical formulation/the mucoadhesive layer at of concentration at about 15% w/w, about 15.5% w/w, about 16.0% w/w, about 16.5% w/w, about 17.0% w/w, about 17.5% w/w, about 18.0% w/w, about 18.5% w/w, about 19.0% w/w, about 19.5% w/w, or about 20.0% w/w. In some embodiments, is présent in the pharmaceutical formulation/the mucoadhesive layer at a concentration from about 15.0% w/w to about 20% w/w, about 15.5% w/w to about 20% w/w, about 16.0% w/w to about 20% w/w, about 16.5% w/w to about 20% w/w, about 17.0% w/w to about 20% w/w, about 17.5% w/w to about 20% w/w, about 18.0% w/w to about 20% w/w, about 18.5% w/w to about 20% w/w, about 19.0% w/w to about 20% w/w, about 19.5% w/w to about 20% w/w, 15.0% w/w to about 20% w/w, about 15.5% w/w to about 20% w/w, about 16.0% w/w to about 20% w/w, about 16.5% w/w to about 20% w/w, about 17.0% w/w to about 20% w/w, about 17.5% w/w to about 20% w/w, about 18.0% w/w to about 20% w/w, about 18.5% w/w to about 20% w/w, about 15.0% w/w to about 19.5% w/w, about 15.0% w/w to about 19.0% w/w, about 15.0% w/w to about 18.5% w/w, about 15.0% w/w to about 18.0% w/w, about 15.0% w/w to about 17.5% w/w, about 15.0% w/w to about 17.0% w/w, about 15.0% w/w to about 16.5% w/w, about 15.0% w/w to about 16.0% w/w, about 15.0% w/w to about 15.5% w/w, about 16% w/w to about 18% w/w, or about 17% w/w to about 19% w/w.
In an embodiment, the mucoadhesive layer further comprises at least one of: an opacifying agent, a colorant, and/or an antioxidant.
In an embodiment, the mucoadhesive layer comprises an antioxidant. In some embodiments, the antioxidant is présent in the pharmaceutical formulation at a concentration of about 0.2% w/w, about 0.3% w/w, about 0.4% w/w, about 0.5% w/w, about 0.6% w/w, about 0.7% w/w, or about 0.8% w/w. In some embodiments, the antioxidant is présent in the pharmaceutical formulation at a concentration of about 0.40% w/w, about 0.41% w/w, about 0.42% w/w, about 0.43% w/w, about 0.44% w/w, about 0.45% w/w, about 0.46% w/w, about 0.47% w/w, about 0.48% w/w, about 0.49% w/w, or about 0.50% w/w. In some embodiments, the antioxidant is présent in the pharmaceutical formulation at a concentration from about 0.2% w/w to about 0.8% w/w, 0.3% w/w to about 0.8% w/w, 0.4% w/w to about 0.8% w/w, 0.5% w/w to about 0.8% w/w, 0.6% w/w to about 0.8% w/w, 0.7% w/w to about 0.8% w/w, 0.2% w/w to about 0.7% w/w, 0.2% w/w to about 0.6% w/w, 0.2% w/w to about 0.5% w/w, 0.2% w/w to about 0.4% w/w, 0.2% w/w to about 0.3% w/w, about 0.3% w/w to about 0.7% w/w, about 0.3% w/w to about 0.6% w/w, about 0.3% w/w to about 0.5% w/w, or about 0.4% w/w to about 0.6% w/w. In some embodiments, the antioxidant is selected from the group comprising butylated hydroxytoluene (BHT), butylated hydroxyanisole, N-acetylcysteine, ascorbyl palmitate, 2,5dihydroxybenzoic acid, propyl gallate, edetic acid, sodium edetate, L-cysteine, sodium metabisulfite, glutathione, cysteine, ascorbic acid and salts thereof, captopril, Na-ascorbate, Na2EDTA, Na2-EDTA-Ca, methimazole, quercetin, arbutin, aloesin, N-acetylglucoseamine, atocopheryl ferulate, MAP (Mg ascorbyl phosphate), sodium benzoate, L-phenylalanine, DMSA (succimer), DPA (D-penicillamine), trientine-HCl, dimercaprol, clioquinol, sodium thiosulfate, TETA (triethylenetetramine), ΤΕΡΑ (tetraethylenepentamine), curcumin, neocuproine, tannin, cuprizone, sodium hydrogen sulfite, lipoic acid, CB3, CB4, CB6, AD4, AD6, AD7, Vitamin E, di-tert-butyl methyl phénols, tert-butyl-methoxyphenols, polyphenols, tocopherols ubiquinones, or caffeic acid. In some embodiments, the antioxidant is BHT.
In an embodiment, the mucoadhesive layer comprises an opacifying agent. In some embodiments, the opacifying agent is présent in the pharmaceutical formulation at a concentration of about 4.0% w/w, about 4.1% w/w, about 4.2% w/w, about 4.3% w/w, about 4.4% w/w, about 4.5% w/w, about 4.6% w/w, about 4.7% w/w, about 4.8% w/w, about 4.9% w/w, or about 5.0% w/w. In some embodiments, the opacifying agent is présent in the pharmaceutical formulation at a concentration from about 4.0% w/w to about 5% w/w, about 4.1% w/w to about 5% w/w, about 4.2% w/w to about 5% w/w, about 4.3% w/w to about 5% w/w, about 4.4% w/w to about 5% w/w, about 4.5% w/w to about 5% w/w, about 4.6% w/w to about 5% w/w, about 4.7% w/w to about 5% w/w, about 4.8% w/w to about 5% w/w, about 4.9% w/w to about 5% w/w, 4.0% w/w to about 4.1% w/w, 4.0% w/w to about 4.2% w/w, 4.0% w/w to about 4.3% w/w, 4.0% w/w to about 4.4% w/w, 4.0% w/w to about 4.5% w/w, 4.0% w/w to about 4.6% w/w, 4.0% w/w to about 4.7% w/w, 4.0% w/w to about 4.8% w/w, 4.0% w/w to about 4.9% w/w, about 4.2% w/w to about 4.8% w/w, about 4.4% w/w to about 4.6% w/w, or about 4.3% w/w to about 4.8% w/w. In some embodiments, the opacifying agent is titanium dioxide.
In an embodiment, the mucoadhesive layer comprises a colorant. In some embodiments, the colorant is present in the pharmaceutical formulation at a concentration of about 0.06% w/w, about 0.07% w/w, about 0.08% w/w, about 0.09% w/w, about 0.10% w/w, about 0.11% w/w, about 0.12% w/w, about 0.13% w/w, or about 0.14% w/w. In some embodiments, the colorant is present in the pharmaceutical formulation at a concentration from about 0.06% w/w to about 0.14% w/w, about 0.07% w/w to about 0.14% w/w, about 0.08% w/w to about 0.14% w/w, about 0.09% w/w to about 0.14% w/w, about 0.10% w/w to about 0.14% w/w, about 0.11% w/w to about 0.14% w/w, about 0.12% w/w to about 0.14% w/w, about 0.13% w/w to about 0.14% w/w, about 0.06% w/w to about 0.14% w/w, about 0.06% w/w to about 0.13% w/w, about 0.06% w/w to about 0.12% w/w, about 0.06% w/w to about 0.11% w/w, about 0.06% w/w to about 0.10% w/w, about 0.06% w/w to about 0.09% w/w, about 0.06% w/w to about 0.08%) w/w, about 0.06%> w/w to about 0.07%) w/w, about 0.06%> w/w to about 0.14%0 w/w, about 0.06% w/w to about 0.12%) w/w, about 0.06%> w/w to about 0.10% w/w, about 0.06% w/w to about 0.08%> w/w, about 0.08% w/w to about 0.14% w/w, about 0.08%> w/w to about 0.12% w/w, about 0.08%> w/w to about 0.10% w/w, about 0.10% w/w to about 0.14%> w/w, about 0.10%o w/w to about 0.12% w/w, or about 0.12%o w/w to about 0.14% w/w. In some embodiments, the colorant is FD&C Yellow No. 6.
Taste modifiers such as flavors, sweeteners, and taste masking agents can be incorporated into the dosage form/pharmaceutical formulation/the mucoadhesive layer to provide a pleasant taste and mouth-feel when the dosage form/pharmaceutical formulation is administered into the oral cavity. In some embodiments, the taste modifier is selected from the group comprising a flavoring agent, a sweetener, a taste making agent or a combination of any thereof. In some embodiments, the flavoring agent is selected from the group comprising naturel mint, peppermint oil, a flavored oil, cocoa powder, or a combination thereof. In some embodiments, the sweetener is selected from the group comprising sodium saccharin, glucose, fructose, aspartame, sucralose, a steviosides, or a combination thereof. In some embodiments, the taste modifier is selected from the group comprising Cremophor® RH-40 (polyoxy 40 hydrogenated castor oil, BASF), clove oil, diglycerides, or a combination thereof. In some embodiments, the taste masking agent is selected from the group comprising Magnasweet 100 (mono-ammonium glycyrrhizinate, Mafco, Inc.), Eudragit E-100 (2-dimethylamino)ethyl méthacrylate polymer, Evonikor any combination thereof. In some embodiments, the taste modifier is selected from the group comprising an essential oil of menthol, a water soluble extract of menthol, wintergreen, peppermint, sweet mint, spearmint, vanillin, cherry, chocolaté, cinnamon, clove, lemon, orange, raspberry, rose, spice, violet, herbal, fruit, strawberry, grape, pineapple, peach, kiwi, papaya, mango, coconut, apple, coffee, plum, watermelon, nuts, durian, green tea, grapefruit, banana, butter or chamomile, sugar, dextrose, lactose, mannitol, sucrose, xylitol, maltitol, acesulfame potassium, talin, glycyrrhizin, sucralose, aspartame, saccharin, sodium saccharin, sodium cyclamate and honey. In some embodiments, the taste modifier is présent in the pharmaceutical formulation at a concentration of about 2.0% w/w, about 2.1% w/w, about 2.2% w/w, about 2.3% w/w, about 2.4% w/w, about 2.5% w/w, about 2.6% w/w, about 2.7% w/w, about 2.8% w/w, about 2.9% w/w, or about 3.0% w/w. In some embodiments, the taste modifier is présent in the pharmaceutical formulation at a concentration of about 2.30% w/w, about 2.31% w/w, about 2.32% w/w, about 2.33% w/w, about 2.34% w/w, about 2.35% w/w, about 2.36% w/w, about 2.37% w/w, about 2.38% w/w, about 2.39% w/w, or about 2.40% w/w. In some embodiments, the taste modifier is présent in the pharmaceutical formulation at a concentration from about 2.0% w/w to about 3.0% w/w, about 2.1% w/w to about 3.0% w/w, about 2.2% w/w to about 3.0% w/w, about 2.3% w/w to about 3.0% w/w, about 2.4% w/w to about 3.0% w/w, about 2.5% w/w to about 3.0% w/w, about 2.6% w/w to about 3.0% w/w, about 2.7% w/w to about 3.0% w/w, about 2.8% w/w to about 3.0% w/w, about 2.9% w/w to about 3.0% w/w, about 2.0% w/w to about 2.9% w/w, about 2.0% w/w to about 2.8% w/w, about 2.0% w/w to about 2.7% w/w, about 2.0% w/w to about 2.6% w/w, about 2.0% w/w to about 2.5% w/w, about 2.0% w/w to about 2.4% w/w, about 2.0% w/w to about 2.3% w/w, about 2.0% w/w to about 2.2% w/w, about 2.0% w/w to about 2.1% w/w, about 2.1% w/w to about 2.3% w/w, about 2.1% w/w to about 2.5% w/w, about 2.1% w/w to about 2.7% w/w, about 2.1% w/w to about 2.9% w/w, about 2.1% w/w to about 2.4% w/w, about 2.1% w/w to about 2.6% w/w, about
2.2% w/w to about 2.4% w/w, about 2.2% w/w to about 2.6% w/w, about 2.2% w/w to about 2.8% w/w, about 2.2% w/w to about 2.5% w/w, about 2.2% w/w to about 2.7 %, about 2.3% w/w to about 2.5% w/w, about 2.3% w/w to about 2.7% w/w, about 2.3% w/w to about 2.9% w/w, about 2.3% w/w to about 2.6 %, about 2.3% w/w to about 2.8%, about 2.4% w/w to about 2.6% w/w, about 2.4% w/w to about 2.8% w/w, about 2.4% w/w to about 2.7% w/w, about 2.4% w/w to about 2.9% w/w, about 2.5% w/w to about 2.7% w/w, about 2.5% w/w to about 2.9% w/w, about 2.5% w/w to about 2.8% w/w, about 2.6% w/w to about 2.8% w/w, about 2.6% w/w to about 2.9% w/w, or about 2.7% w/w to about 2.9% w/w.
In an embodiment, the pharmaceutical formulation further comprises a soft backing. In some embodiments, the soft backing is a polymer film. In some embodiments, the soft backing is an occlusive backing layer. In some embodiments, the soft backing comprises an ethylene-vinyl acetate (EVA) polymer (e.g., CoTran 9715 EVA film). In some embodiments, the soft backing has a thickness of at least about 0.5 mils, about 1 mils, about 1.5 mils, about 2 mils, about 2.5 mils, about 3 mils, about 3.5 mils, about 4 mils, about 4.5 mils, or about 5 mils. In some embodiments, the soft backing has a thickness of between about 0.5 mils to about 5 mils, about 1 mils to about 5 mils, about 1.5 mils to about 5 mils, about 2 mils to about 5 mils, about 2.5 mils to about 5 mils, about 3 mils to about 5 mils, about 3.5 mils to about 5 mils, about 4 mils to about 5 mils, about 4.5 mils to about 5 mils, 0.5 mils to about 4.5 mils, about 1 mils to about 4.5 mils, about 1.5 mils to about 4.5 mils, about 2 mils to about 4.5 mils, about 2.5 mils to about 4.5 mils, about 3 mils to about 4.5 mils, about 3.5 mils to about 4.5 mils, about 4 mils to about 4.5 mils, about 0.5 mils to about 4 mils, about 1 mils to about 4 mils, about 1.5 mils to about 4 mils, about 2 mils to about 4 mils, about 2.5 mils to about 4 mils, about 3 mils to about 4 mils, about 3.5 mils to about 4 mils, about 0.5 mils to about 3.5 mils, about 1 mils to about 3.5 mils, about 1.5 mils to about 3.5 mils, about 2 mils to about 3.5 mils, about 2.5 mils to about 3.5 mils, about 3 mils to about 3.5 mils, about 0.5 mils to about 3 mils, about 1 mils to about 3 mils, about 1.5 mils to about 3 mils, about 2 mils to about 3 mils, about 2.5 mils to about 3 mils, about 0.5 mils to about 2.5 mils, about 1 mils to about 2.5 mils, about 1.5 mils to about 2.5 mils, about 2 mils to about 2.5 mils, about 0.5 mils to about 2 mils, about 1 mils to about 2 mils, about 1.5 mils to about 2 mils, about 0.5 mils to about 1.5 mils, about 1 mils to about 1.5 mils, or about 0.5 mils to about 1 mils.
In one aspect, the mucosal adhesive pharmaceutical film includes an occlusive backing layer. In some embodiments, the occlusive backing layer is substantially free of isotretinoin. In some embodiments, the occlusive backing layer is ingestible.
In an embodiment, the occlusive backing layer comprises one of more méthacrylate based co-polymers. In some embodiments, the ingestible, occlusive backing layer comprises a polymer selected from the group consisting of poly(methacrylic acid-co-ethylacrylate) 1:1, poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2 and combinations thereof.
In some embodiments, the mucoadhesive layer and/or the occlusive backing layer further comprise a plasticizer. In some embodiments, the occlusive backing layer comprises a plasticizer. In some embodiments, the plasticizer is propylene glycol and/or a PEG. In some embodiments, the PEG has a weight average molecular weight of about 380 g/mol to about 420 g/mol. In some embodiments, the PEG is PEG 400.
In some embodiments, the occlusive backing layer further comprises at least one of: an opacifying agent and/or a colorant. In some embodiments, the mucoadhesive layer comprises a colorant and the occlusive backing layer comprises a colorant different than that in the mucoadhesive layer. In some embodiments, the mucoadhesive layer is colored yellow. In some embodiments, the occlusive backing layer is colored red.
Also provided is a multilayered pharmaceutical formulation comprising a pharmaceutical formulation disclosed herein. In some embodiments, the multilayered pharmaceutical formulation comprises 2 layers, 3 layers, 4 layers or 5 layers. In some embodiments, the multilayered pharmaceutical formulation is a dual layer (2 layer) oral mucosal film.
In an embodiment, the multilayered pharmaceutical formulation comprises: (1) a first layer comprising isotretinoin or a pharmaceutically acceptable sait thereof and a mucoadhesive polymer; and (2) a second layer comprising an ingestible backing film. In some embodiments, the first layer is a mucoadhesive layer as described herein. In some embodiments, the second layer is a occlusive backing layer as described herein.
In an embodiment, the second layer of the multilayered pharmaceutical formulation comprises a methacrylate-based polymer. In some embodiments, the second layer ofthe multilayered formulation comprises 1, 2, 3, 4, or 5 methacrylate-based polymers. In some embodiments, the second layer of the multilayered formulation comprises 2 methacrylate-based polymers. In some embodiments, the total concentration ofthe 1, 2, 3, 4 or 5 polymethacrylatebased polymers présent in the second layer of the multilayered pharmaceutical formulation is about 65% w/w, about 66% w/w, about 67% w/w, about 68% w/w, about 69% w/w, about 70% w/w, about 71% w/w, about 72% w/w, about 73% w/w, about 74% w/w, or about 75% w/w. In some embodiments, the total concentration ofthe 1, 2, 3, 4 or 5 methacrylate-based polymers présent in the second layer of the multilayered pharmaceutical formulation is from about 65.0% w/w to about 75.0% w/w, about 66.0% w/w to about 75.0% w/w, about 67.0% w/w to about 75.0% w/w, about 68.0% w/w to about 75.0% w/w, about 69.0% w/w to about 75.0% w/w, about 70.0% w/w to about 75.0% w/w, about 71.0% w/w to about 75.0% w/w, about 72.0% w/w to about 75.0% w/w, about 73.0% w/w to about 75.0% w/w, about 74.0% w/w to about 75.0% w/w, about 65.0% w/w to about 74.0% w/w, about 65.0% w/w to about 73.0% w/w, about 65.0% w/w to about 72.0% w/w, about 65.0% w/w to about 71.0% w/w, about 65.0% w/w to about 70.0% w/w, about 65.0% w/w to about 69.0% w/w, about 65.0% w/w to about 68.0% w/w, about 65.0% w/w to about 67.0% w/w, about 65.0% w/w to about 66.0% w/w, about 66.0% w/w to about 68.0% w/w, about 66.0% w/w to about 70.0% w/w, about 66.0% w/w to about 72.0% w/w, about 66.0% w/w to about 74.0% w/w, about 66.0% w/w to about 69.0% w/w, about 66.0% w/w to about 71.0% w/w, about 67.0% w/w to about 69.0% w/w, about 67.0% w/w to about 71.0% w/w, about 67.0% w/w to about 73.0% w/w, about 67.0% w/w to about 70.0% w/w, about 67.0% w/w to about 72.0 %, about 68.0% w/w to about 70.0% w/w, about 68.0% w/w to about 72.0% w/w, about 68.0% w/w to about 74.0% w/w, about 68.0% w/w to about 71.0 %, about 68.0% w/w to about 73.0%, about 69.0% w/w to about 71.0% w/w, about 69.0% w/w to about 73.0% w/w, about 69.0% w/w to about 72.0% w/w, about 69.0% w/w to about 74.0% w/w, about 70.0% w/w to about 72.0% w/w, about 70.0% w/w to about 74.0% w/w, about 70.0% w/w to about 73.0% w/w, about 71.0% w/w to about 73.0% w/w, about 71.0% w/w to about 74.0% w/w, or about 72.0% w/w to about 74.0% w/w.
In an embodiment, the methacrylate-based polymer is an Eudragit® polymer, i.e. a poly(methacrylate). As contemplated herein such polymers form part of the disclosed films, for example, and not part of a common tablet coating. For example, in some embodiments, as disclosed herein, a disclosed poly(methacrylate) (such as a Eudragit® polymer) may be used as ingestible backing film for isotretinoin oral film to provide substantially one-direction perméation when the film is applied on oral mucosal tissues. In some embodiments, a contemplated poly(methacrylate) is Eudragit L100-55, Eudragit RL PO, or a combination of both, i.e., ethyl-acrylate-methacrylic acid polymer (e.g., (e.g., poly(methacrylic acid-coethylacrylate) 1:1) and/or co-polymers of ethyl acetate, methyl méthacrylate and methacrylic acid. In some embodiments, the second layer of the multilayered pharmaceutical formulation comprises Eudragit L100-55 and Eudragit RL PO.
In some embodiments, an Eudragit L100-55 polymer (e.g., poly(methacrylic acid-coethylacrylate) 1:1) is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 40.0% w/w, about 40.5% w/w, about 41.0% w/w, about 41.5% w/w, about 42.0% w/w, about 42.5% w/w, about 43.0% w/w, about 43.5% w/w, about 44.0% w/w, about 44.5% w/w, or about 45.0% w/w. In some embodiments, the Eudragit L100-55 is présent in the second layer of the multilayered pharmaceutical formulation at a concentration from about 40.0% w/w to about 45.0% w/w, about 40.5% w/w to about 45.0% w/w, about 41.0% w/w to about 45.0% w/w, about 41.5% w/w to about 45.0% w/w, about 42.0% w/w to about 45.0% w/w, about 42.5% w/w to about 45.0% w/w, about 43.0% w/w to about 45.0% w/w, about 43.5% w/w to about 45.0% w/w, about 44.0% w/w to about 45.0% w/w, about 44.5% w/w to about 45.0% w/w, about 40.0% w/w to about 44.5% w/w, about 40.0% w/w to about 44.0% w/w, about 40.0% w/w to about 43.5% w/w, about 40.0% w/w to about 43.0% w/w, about 40.0% w/w to about 42.5% w/w, about 40.0% w/w to about 42.0% w/w, about 40.0% w/w to about 41.5% w/w, about 40.0% w/w to about 41.0% w/w, about 40.0% w/w to about 40.5% w/w, about 40.5% w/w to about 41.5% w/w, about 40.5% w/w to about 42.5% w/w, about 40.5% w/w to about 43.5% w/w, about 40.5% w/w to about 44.5% w/w, about 40.5% w/w to about 42.0% w/w, about 40.5% w/w to about 43.0% w/w, about 41.0% w/w to about 42.0% w/w, about 41.0% w/w to about 43.0% w/w, about 41.0% w/w to about 44.0% w/w, about 41.0% w/w to about 42.5% w/w, about 41.0% w/w to about 43.5 %, about 41.5% w/w to about 42.5% w/w, about 41.5% w/w to about 43.5% w/w, about 41.5% w/w to about 44.5% w/w, about 41.5% w/w to about 43.0 %, about 41.5% w/w to about 44.0%, about 42.0% w/w to about 43.0% w/w, about 42.0% w/w to about 44.0% w/w, about 42.0% w/w to about 43.5% w/w, about 42.0% w/w to about 44.5% w/w, about 42.5% w/w to about 43.5% w/w, about 42.5% w/w to about 44.5% w/w, about 42.5% w/w to about
44.0% w/w, about 43.0% w/w to about 44.0% w/w, about 43.0% w/w to about 44.5% w/w, or about 43.5% w/w to about 44.5% w/w.
In some embodiments, an Eudragit RL PO (i.e., poly (ethyl acrylate, methyl méthacrylate, trmethylammonioethyl méthacrylate chloride 1:2:0.2) is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 25.0% w/w, about 25.5% w/w, about 26.0% w/w, about 26.5% w/w, about 27.0% w/w, about 27.5% w/w, about 28.0% w/w, about 28.5% w/w, about 29.0% w/w, about 29.5% w/w, or about 30.0% w/w. In some embodiments, the Eudragit RL PO is présent in the second layer of the multilayered pharmaceutical formulation at a concentration from about 25.0% w/w to about 30.0% w/w, about 25.5% w/w to about 30.0% w/w, about 26.0% w/w to about 30.0% w/w, about 26.5% w/w to about 30.0% w/w, about 27.0% w/w to about 30.0% w/w, about 27.5% w/w to about 30.0% w/w, about 28.0% w/w to about 30.0% w/w, about 28.5% w/w to about 30.0% w/w, about 29.0% w/w to about 30.0% w/w, about 29.5% w/w to about 30.0% w/w, about 25.0% w/w to about 29.5% w/w, about 25.0% w/w to about 29.0% w/w, about 25.0% w/w to about 28.5% w/w, about 25.0% w/w to about 28.0% w/w, about 25.0% w/w to about 27.5% w/w, about 25.0% w/w to about 27.0% w/w, about 25.0% w/w to about 26.5% w/w, about 25.0% w/w to about 26.0% w/w, about 25.0% w/w to about 25.5% w/w, about 25.5% w/w to about 26.5% w/w, about 25.5% w/w to about 27.5% w/w, about 25.5% w/w to about 28.5% w/w, about 25.5% w/w to about 29.5% w/w, about 25.5% w/w to about 27.0% w/w, about 25.5% w/w to about 28.0% w/w, about 26.0% w/w to about 27.0% w/w, about 26.0% w/w to about 28.0% w/w, about 26.0% w/w to about 29.0% w/w, about 26.0% w/w to about 27.5% w/w, about 26.0% w/w to about 28.5 %, about 26.5% w/w to about 27.5% w/w, about 26.5% w/w to about 28.5% w/w, about 26.5% w/w to about 29.5% w/w, about 26.5% w/w to about 28.0 %, about 26.5% w/w to about 29.0%, about 27.0% w/w to about 28.0% w/w, about 27.0% w/w to about 29.0% w/w, about 27.0% w/w to about 28.5% w/w, about 27.0% w/w to about 29.5% w/w, about 27.5% w/w to about 28.5% w/w, about 27.5% w/w to about 29.5% w/w, about 27.5% w/w to about 29.0% w/w, about 28.0% w/w to about 29.0% w/w, about 28.0% w/w to about 29.5% w/w, or about 28.5% w/w to about 29.5% w/w.
In some embodiments, the second layer of the multilayered pharmaceutical formulation further comprises an opacifying agent. In some embodiments, the opacifying agent is titanium dioxide. In some embodiments, the opacifying agent is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 7.0% w/w, about 7.1% w/w, about 7.2% w/w, about 7.3% w/w, about 7.4% w/w, about 7.5% w/w, about 7.6% w/w, about 7.7% w/w, about 7.8% w/w, about 7.9% w/w, or about 8.0% w/w. In some embodiments, the opacifying agent is présent in the second layer of the multilayered pharmaceutical formulation at a concentration from about 7.0% w/w to about 8% w/w, about 7.1% w/w to about 8% w/w, about 7.2% w/w to about 8% w/w, about 7.3% w/w to about 8% w/w, about 7.4% w/w to about 8% w/w, about 7.5% w/w to about 8% w/w, about 7.6% w/w to about 8% w/w, about 7.7% w/w to about 8% w/w, about 7.8% w/w to about 8% w/w, about 7.9% w/w to about 8% w/w, 7.0% w/w to about 7.1% w/w, 7.0% w/w to about 7.2% w/w, 7.0% w/w to about 7.3% w/w, 7.0% w/w to about 7.4% w/w, 7.0% w/w to about 7.5% w/w, 7.0% w/w to about 7.6% w/w, 7.0% w/w to about 7.7% w/w, 7.0% w/w to about 7.8% w/w, 7.0% w/w to about 7.9% w/w, about 7.2% w/w to about 7.8% w/w, about 7.4% w/w to about 7.6% w/w, or about 7.3% w/w to about 7.8% w/w.
In some embodiments, the second layer of the multilayered pharmaceutical formulation further comprises a colorant. In some embodiments, the colorant is a FD&C approved red colorant, e.g., 5404 FD&C Red No. 40. In some embodiments, the colorant is présent in the second layer ofthe multilayered pharmaceutical formulation at a concentration of about 0.3% w/w, about 0.4% w/w, about 0.5% w/w, about 0.6% w/w, about 0.7% w/w, about 0.8% w/w, or about 0.9% w/w. In some embodiments, the colorant is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 0.45% w/w, about 0.46% w/w, about 0.47% w/w, about 0.48% w/w, about 0.49% w/w, about 0.50% w/w, about 0.51% w/w, about 0.52% w/w, about 0.53% w/w, about 0.54% w/w, or about 0.55% w/w. In some embodiments, the colorant is présent in the second layer of the multilayered pharmaceutical formulation at a concentration from about 0.3% w/w to about 0.9% w/w, 0.4% w/w to about
0.9% w/w, 0.5% w/w to about 0.9% w/w, 0.6% w/w to about 0.9% w/w, 0.7% w/w to about
0.9% w/w, 0.8% w/w to about 0.9% w/w, 0.3% w/w to about 0.8% w/w, 0.3% w/w to about
0.7% w/w, 0.3% w/w to about 0.6% w/w, 0.3% w/w to about 0.5% w/w, 0.3% w/w to about
0.4% w/w, about 0.4% w/w to about 0.8% w/w, about 0.4% w/w to about 0.7% w/w, about 0.4% w/w to about 0.6% w/w, or about 0.5% w/w to about 0.7% w/w.
In some embodiments, the second layer of the multilayered pharmaceutical formulation further comprises a plasticizer. In some embodiments, the second layer of the multilayered pharmaceutical formulation comprises 1, 2, 3, 4, or 5 plasticizers. In some embodiments, the total concentration of plasticizer in the second layer of the multilayered pharmaceutical formulation is about 5% w/w, about 7.5%, about 10% w/w, about 12.5% w/w, about 15% w/w, about 17.5% w/w, about 20% w/w, about 22.5% w/w, about 25% w/w, about 27.5% w/w, or about 30% w/w. In some embodiments, the total concentration of plasticizer in the second layer ofthe multilayered pharmaceutical formulation is from about 5% w/w to about 30% w/w, about 5% w/w to about 25% w/w, about 5% w/w to about 20% w/w, about 5% w/w to about 15% w/w, about 5% w/w to about 10% w/w, about 10% w/w to about 30% w/w, about 15% w/w to about 30% w/w, about 20% w/w to about 30% w/w, about 25% w/w to about 30% w/w, about 10% w/w to about 25% w/w, about 10% w/w to about 20% w/w, about 10% w/w to about 15% w/w, about 15% w/w to about 25% w/w, about 15% w/w to about 20% w/w, or about 20% w/w to about 25% w/w. In some embodiments, the second layer of the multilayered pharmaceutical formulation comprises propylene glycol and/or a PEG. In some embodiments, the second layer of the multilayered pharmaceutical fomrulation comprises propylene glycol and a PEG. In some embodiments, the PEG is PEG 400. In some embodiments, the PEG is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 12% w/w, about 13% w/w, about 14% w/w, about 15% w/w, about 16% w/w, or about 17% w/w. In some embodiments, the PEG is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 14.5% w/w, about 14.6% w/w, about 14.7% w/w, about 14.8% w/w, about 14.9% w/w, about 15.0% w/w, about 15.1% w/w, about 15.2% w/w, about 15.3% w/w, about 15.4% w/w, or about 15.5% w/w. In some embodiments, the PEG is présent in the second layer of the multilayered phannaceutical fonnulation at a concentration from about 12% w/w to about 17% w/w, about 13% w/w to about 17% w/w, about 14% w/w to about 17% w/w, about 15% w/w to about 17% w/w, about 16% w/w to about 17% w/w, about 12% w/w to about 16% w/w, about 12% w/w to about 15% w/w, about 12% w/w to about 14% w/w, about 12% w/w to about 13% w/w, about 13% w/w to about 14% w/w, about 13% to about 15% w/w, about 13% w/w to about 16% w/w, about 13% w/w to about 17% w/w, about 14% w/w to about 15% w/w, about 14% w/w to about 16% w/w, about 14% w/w to about 17% w/w, about 15% w/w to about 16% w/w, about 15% w/w to about 17% w/w, or about 16% w/w to about 17% w/w. In some embodiments, the propylene glycol is présent in the second layer of the multilayered pharmaceutical formulation at a concentration of about 2% w/w, about 3% w/w, about 4% w/w, about 5% w/w, about 6% w/w, or about 7% w/w. In some embodiments, the propylene glycol is présent in the second layer of the multilayered phannaceutical fonnulation at a concentration of about 5% w/w, about 5.1% w/w, about 5.2% w/w, about 5.3% w/w, about 5.4% w/w, about 5.5% w/w, about 5.6% w/w, about 5.7% v/hw, about 5.8% w/w, about 5.9% w/w, or about 6.0% w/w. In some embodiments, the propylene glycol is présent in the second layer of the multilayered pharmaceutical formulation at a concentration from about 2% w/w to about 7% w/w, about 3% w/w to about 7% w/w, about 4% w/w to about 7% w/w, about 5% w/w to about 7% w/w, about 6% w/w to about 7% w/w, about 2% w/w to about 6% w/w, about 2% w/w to about 5% w/w, about 2% w/w to about 4% w/w, about 2% w/w to about 3% w/w, about 3% w/w to about 4% w/w, about 3% to about 5% w/w, about 3% w/w to about 6% w/w, about 3% w/w to about 7% w/w, about 4% w/w to about 5% w/w, about 4% w/w to about 6% w/w, about 4% w/w to about 7% w/w, about 5% w/w to about 6% w/w, about 5% w/w to about 7% w/w, or about 6% w/w to about 7% w/w. In some embodiments, the second layer ofthe multilayered pharmaceutical formulation comprises about 15% w/w to about 16% w/w PEG 400 and about 5% w/w to about 6% w/w propylene glycol.
In an embodiment, more than 75%, 80%, 85%, 90%, 95% or 100% ofthe isotretinoin is released within 60 minutes using an USP 3 or a USP 7 dissolution apparatus. In some embodiments, more than 85% of the isotretinoin is released within 60 minutes using a USP 3 or 7 dissolution apparatus. In an embodiment, more than 75%, 80%, 85%, 90%, 95% or 100% of the isotretinoin is released within 20 minutes using a USP 3 and 7 dissolution apparatus. In some embodiments, more than 85% of the isotretinoin is released within 20 minutes using a USP 3 or 7 dissolution apparatus. In an embodiment, more than 75%, 80%, 85%, 90%, 95% or 100% of the isotretinoin is released within 15 minutes using a USP 3 and 7 dissolution apparatus. In some embodiments, more than 85% of the isotretinoin is released within 15 minutes using a USP 3 or 7 dissolution apparatus. In an embodiment, the drug release method is described in Example 1.
In some embodiments, a pharmaceutical formulation disclosed herein is stable at 25 °C/60% RH for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months using ICH stability testing requirements. In some embodiments, a pharmaceutical formulation disclosed herein is stable at 40 °C/75% RH for 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months using ICH stability testing requirements. In some embodiments, the ICH stability testing requirements are Guideline ICH Q1A (R2) and ICH Q1E Evaluation of Stability Data.
Also provided herein is mucosal adhesive pharmaceutical film comprising: a mucoadhesive layer comprising about 0.1% w/w, about 0.2% w/w or about 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 12% w/w to about 15% w/w vinylpyrrolidone-vinyl acetate copolymer, about 53% w/w to about 57% w/w PVP, about 16% w/w to about 19% w/w PEG 400 and about 4% w/w to about 6% w/w propylene glycol; and an occlusive backing layer. In some embodiments, the occlusive backing layer comprising about 40% w/w to about 45% w/w poly(methacrylic acid-co-ethylacrylate) 1:1, about 25% w/w to about 30% w/w poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2, about 13% w/w to about 16% w/w PEG 400 and about 4% w/w to about 6% w/w propylene glycol.
Also provided herein is a pharmaceutical formulation comprising: about 0.15% to about 0.35% w/w isotretinoin; and about 10% to about 20% w/w polycarbophil (e.g., Noveon).
Also provided herein is a pharmaceutical formulation comprising: about 0.2% w/w isotretinoin; and about 10% to about 20% w/w polycarbophil.
Also provided herein is a pharmaceutical formulation comprising: about 0.3% w/w isotretinoin; and about 20% to about 80% w/w of a dissolvable or an ingestible backing film.
Also provided herein is a multilayered pharmaceutical formulation, wherein the formulation comprises a first layer comprising: about 0.2% to about 0.4% w/w isotretinoin; and about 70% to about 80% w/w polyvinylpyrrolidone (PVP) (e.g. Kollidon); and a second layer comprising a backing film.
In one embodiment, the backing film is ingestible.
In one embodiment, the backing film comprises a polymethacrylate-based polymer, e.g., ethyl-acrylate-methacrylic acid polymer and/or copolymers of ethyl acrylate, methyl méthacrylate and methacrylic acid, e.g., Eudragit, e.g., Eudragit Ll00-55, and Eudragit RL PO.
The films can be stand-alone or self-supporting, meaning the films hâve enough integrity so that there is no need to support them with additional backings, such as nondissolvable films, such as polyethylene films.
Also, preservatives or stabilizers can be added when needed. Preservatives can include anti-microbial agents and non-organic compounds, and are exemplified by sodium benzoate, parabens and dérivatives, sorbic acid and salts, propionic acids and salts, sulfur dioxide and sulfites, acetic acid and acétates, nitrites and nitrates, and the like.
In some embodiments, a dosage form is a single layer oral mucosal fdm. In some embodiments, a dosage form is a dual layer oral mucosal film.
The dosage form (single or dual layer film) can for example be square, rectangular, circular, oval, or any number of shapes. In some embodiments, the dosage form is square. Square dosage forms can be for example hâve sides about 1-4 inches in length. In some embodiments, the dosage form is a square with sides of a length about 0.25 inches, about 0.50 inches, about 0.75 inches, about 1 inch, about 1.25 inches, about 1.50 inches, about 1.75 inches, about 2 inches, about 2.25 inches, about 2.50 inches, about 2.75 inches, or about 3 inches. In some embodiments, the dosage form is circular. Circular (disk) dosage forms can be for example 1-4 inches in diameter. In some embodiments, the dosage form is circular with a diameter of about 0.25 inches, about 0.50 inches, about 0.75 inches, about 1 inch, about 1.25 inches, about 1.50 inches, about 1.75 inches, about 2 inches, about 2.25 inches, about 2.50 inches, about 2.75 inches, or about 3 inches.
In some embodiments, the dosage form (single or dual layer) is about 30 mil (0.762 mm) or less in thickness. In some embodiments, the dosage form (single or dual layer) is about 29 mil or less, or about 28 mil or less, about 27 mil or less, about 26 mil or less, about 25 mil or less, about 24 mil or less, about 23 mil or less, about 22 mil or less, about 21 mil or less, about 20 mil (0.508 mm) or less, about 19 mil or less, about 18 mil or less, about 17 mil or less, about 16 mil or less, about 15 mil or less, about 14 mil or less, about 13 mil or less, about 12 mil or less, about 11 mil or less, about 10 mil (0.254 mm) or less, about 9 mil or less or about 8 mil or less in thickness. In some embodiments, the dosage form (single or dual layer film) is about 1 mil or more, about 2 mil or more, about 3 mil or more, about 4 mil or more, about 5 mil or more, about 6 mil or more, about 7 mil or more, about 8 mil or more, about 9 mil or more, about 10 mil or more, about 11 mil or more, about 12 mil or more, about 13 mil or more, about 14 mil or more, or about 15 mil or more, about 16 mil or more, about 17 mil or more, about 18 mil or more, about 19 mil or more, or about 20 mil or more in thickness.
In some embodiments, the dosage form area (e.g., length x width, single or dual layer film) is about 20 cm2 or less, about 19 cm2 or less, about 18 cm2 or less, about 17 cm2 or less, about 16 cm or less, about 15 cm or less, about 14 cm or less, about 13 cm or less, about 12 2 2 2 2 2 cm or less, about 11 cm or less, about 10 cm or less, about 9 cm or less, about 8 cm or less,
2 2 2 2 about 7 cm or less, about 6 cm or less, about 5 cm or less, about 4 cm or less, about 3 cm or less, or about 2 cm2 or less. In certain embodiments, the dosage form area (single or dual layer) is about 1 cm2 or more, about 2 cm2 or more, about 3 cm2 or more, about 4 cm2 or more, or about 5 cm or more.
In some embodiments, the dosage form area (single or dual layer film) is about equal to the area of an oral premalignant lésion. In some embodiments, the dosage form area (single or dual layer film) is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 225%, about 250%, about 275%, about 300%, about 325%, about 350%, about 375%, about 400%, about 425%, about 450%, or about 500% larger than the area of an oral premalignant lésion. In some embodiments, the dosage form area (single or dual layer film) is about 2x, about 3x, about 4x, about 5x, about 6x, about 7x, about 8x, about 9x, about lOx, about llx, about 12x, about 13x, about 14x, about 15x, about 16x, about 17x, about 18x, about 19x, about 20x, about 25x, about 30x, about 35x, about 40x, about 45x, about 50x, about 55x, about 60x, about 65x, about 70x, about 75x, about 80x, about 85x, about 90x, about 95x, about lOOx, about lOOx, about HOx, about 120x, about 130x, about 140x, about 150x, about 160x, about 170x, about 180x, about 190x, about 200x, about 225x, about 250x, about 275x, about 300x, about 325x, about 350x, about 375x, about 400x, about 425x, about 450x, or about 500x larger than the area of an oral premalignant lésion. It can be appreciated that a disclosed film may be customized in size (or capable of customization by e.g., simple cutting) to treat a particular size of lésion.
In some embodiments, the weight of a single dosage form (single or dual layer) is about 200 mg or less, about 190 mg or less, about 180 mg or less, about 170 mg or less, about 160 mg or less, about 150 mg or less, about 140 mg or less, about 130 mg or less, about 120 mg or less, about 110 mg or less, about 100 mg or less, about 90 mg or less, about 80 mg or less, about 70 mg or less, about 60 mg or less, about 50 mg or less, about 40 mg or less, or about 30 mg or less. In some embodiments, the weight of a single dosage form weight (single or dual layer) is about 20 mg or more, about 30 mg or more, about 40 mg or more, about 50 mg or more, about 60 mg or more, about 70 mg or more, about 80 mg or more, about 90 mg or more, about 100 mg or more, about 110 mg or more, about 120 mg or more, about 130 mg or more, about 140 mg or more, about 150 mg or more, about 160 mg or more, about 170 mg or more, about 180 mg or more, about 190 mg or more or about 200 mg or more.
In some embodiments, the weight of isotretinoin, or a pharmaceutically acceptable sait thereof, in the single dosage form is about 0.05 mg, about 0.075mg, about 0.1 mg, about 0.125 mg, about 0.15 mg, about 0.175 mg, about 0.2 mg, about 0.225 mg, about 0.25 mg, about 0.275 mg, about 0.3 mg, about 0.325 mg, about 0.35 mg, about 0.375 mg, about 0.4 mg, about 0.425 mg, about 0.45 mg, 0.475 mg, or about 0.5 mg. In some embodiments, the weight of isotretinoin, or a pharmaceutically acceptable sait thereof, in the single dosage form is from about 0.05 mg to 10 about 0.5 mg, about 0.075 mg to about 0.5 mg, about 0.1 mg to about 0.5 mg, about 0.125 mg to about 0.5 mg, about 0.15 mg to about 0.5 mg, about 0.175 mg to about 0.5 mg, about 0.2 mg to about 0.5 mg, about 0.225 mg to about 0.5 mg, about 0.25 mg to about 0.5 mg, about 0.275 mg to about 0.5 mg, about 0.3 mg to about 0.5 mg, about 0.325 mg to about 0.5 mg, about 0.35 mg to about 0.5 mg, about 0.375 mg to about 0.5 mg, about 0.4 mg to about 0.5 mg, about 0.425 mg 15 to about 0.5 mg, about 0.45 mg to about 0.5 mg, about 0.475 mg to about 0.5 mg, about 0.05 mg to about 0.475 mg, about 0.05 mg to about 0.45 mg, about 0.05 mg to about 0.425 mg, about 0.05 mg to about 0.4 mg, about 0.05 mg to about 0.375 mg, about 0.05 mg to about 0.35 mg, about 0.05 mg to about 0.325 mg, about 0.05 mg to about 0.3 mg, about 0.05 mg to about 0.275 mg, about 0.05 mg to about 0.25 mg, about 0.05 mg to about 0.225 mg, about 0.05 mg to about
0.2 mg, about 0.05 mg to about 0.175 mg, about 0.05 mg to about 0.15 mg, about 0.05 mg to about 0.125 mg, about 0.05 mg to about 0.1 mg, about 0.05 mg to about 0.075 mg, about 0.1 mg to about 0.2 mg, about 0.1 mg to about 0.3 mg, about 0.1 mg to about 0.4 mg, about 0.15 mg to about 0.25 mg, about 0.15 mg to about 0.35 mg, about 0.15 mg to about 0.45 mg, about 0.2 mg to about 0.3 mg, about 0.2 mg to about 0.4 mg, about 0.25 mg to about 0.35 mg, about 0.25 mg to about 0.45 mg, about 0.3 mg to about 0.4 mg, or about 0.35 mg to about 0.45 mg.
In some embodiments, the distribution of isotretinoin, or pharmaceutically acceptable 2 2 sait thereof, in the dosage form is about 0.025 mg/inch , about 0.05 mg/inch , about 0.075 mg/inch , about 0.1 mg/inch , about 0.125 mg/inch , about 0.15 mg/inch , about 0.175 mg/inch , about 0.2 mg/inch2, about 0.225 mg/inch2, about 0.25 mg/inch2, about 0.275 mg/inch2, about 0.3 30 mg/inch2, about 0.325 mg/inch2, about 0.35 mg/inch2, about 0.375 mg/inch2, about 0.4 mg/inch2, about 0.425 mg/inch2, about 0.45 mg/inch2, about 0.475 mg/inch2, or about 0.5 mg/inch2. In some embodiments, the distribution of isotretinoin, or pharmaceutically acceptable sait thereof, in the dosage form is from about 0.025 mg/inch2 to about 0.5 mg/inch2, about 0.05 mg/inch2 to about 0.5 mg/inch2, about 0.075 mg/inch2 to about 0.5 mg/inch2, about 0.1 mg/inch2 to about 0.5 mg/inch2, about 0.125 mg/inch2 to about 0.5 mg/inch2, about 0.15 mg/inch2 to about 0.5 mg/inch2, about 0.175 mg/inch2 to about 0.5 mg/inch2, about 0.2 mg/inch2 to about 0.5 mg/inch2, about 0.225 mg/inch2 to about 0.5 mg/inch2, about 0.25 mg/inch2 to about 0.5 mg/inch2, about 0.275 mg/inch2 to about 0.5 mg/inch2, about 0.3 mg/inch2 to about 0.5 mg/inch2, about 0.325 mg/inch2 to about 0.5 mg/inch2, about 0.35 mg/inch2 to about 0.5 mg/inch2, about 0.375 mg/inch2 to about 0.5 mg/inch2, about 0.4 mg/inch2 to about 0.5 mg/inch2, about 0.425 mg/inch2 to about 0.5 mg/inch2, about 0.45 mg/inch2 to about 0.5 mg/inch2, about 0.475 mg/inch2 to about 0.5 mg/inch2, about 0.025 mg/inch2 to about 0.475 mg/inch2, about 0.025 mg/inch2 to about 0.45 mg/inch2, about 0.025 mg/inch2 to about 0.425 mg/inch2, about 0.025 mg/inch2 to about 0.4 mg/inch2, about 0.025 mg/inch2 to about 0.375 mg/inch2, about 0.025 mg/inch2 to about 0.35 mg/inch2, about 0.025 mg/inch2 to about 0.325 mg/inch2, about 0.025 mg/inch2 to about 0.3 mg/inch2, about 0.025 mg/inch2 to about 0.275 mg/inch2, about 0.025 mg/inch2 to about 0.25 mg/inch2, about 0.025 mg/inch2 to about 0.225 mg/inch2, about 0.025 mg/inch2 to about 0.2 mg/inch2, about 0.025 mg/inch2 to about 0.175 mg/inch2, about 0.025 mg/inch2 to about 0.15 mg/inch2, about 0.025 mg/inch2 to about 0.125 mg/inch2, about 0.025 mg/inch2 to about 0.1 mg/inch2, about 0.025 mg/inch2 to about 0.075 mg/inch2, about 0.025 mg/inch2 to about 0.05 mg/inch2, about 0.05 mg/inch2 to about 0.15 mg/inch2, about 0.05 mg/inch2 to about 0.25 mg/inch2, about 0.05 mg/inch2 to about 0.35 mg/inch2, about 0.05 mg/inch2 to about 0.45 mg/inch2, about 0.1 mg/inch2 to about 0.2 mg/inch2, about 0.1 mg/inch2 to about 0.3 mg/inch2, about 0.1 mg/inch2 to about 0.4 mg/inch2, about 0.15 mg/inch2 to about 0.25 mg/inch2, about 0.15 mg/inch2 to about 0.35 mg/inch2, about 0.15 mg/inch2 to about 0.45 mg/inch2, about 0.2 mg/inch2 to about 0.3 mg/inch2, about 0.2 mg/inch2 to about 0.4 mg/inch2, about 0.25 mg/inch2 to about 0.35 mg/inch2, about 0.25 mg/inch2 to about 0.45 mg/inch2, about 0.3 mg/inch2 to about 0.4 mg/inch2, or about 0.35 mg/inch2 to about 0.45 mg/inch2.
More than one dosage form can be used at each administration, such as 1 -4 dosage forms per administration. Dosages of isotretinoin may be for example from 0.01 mg per administration to 100 mg per administration or from 0.01 mg per administration to 500 mg per administration or from 0.01 mg per administration to 1g per administration. Administrations can be repeated as appropriate, and the release profile provided by preceding administrations.
Pharmaceutical Salts
Pharmaceutically Acceptable Salts
Pharmaceutically acceptable salts of isotretinoin used in the pharmaceutical formulations described herein are also contemplated for the uses described herein. “Pharmaceutically acceptable sait” refers to any sait of isotretinoin which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Pharmaceutically acceptable salts may be derived from a variety of organic and inorganic counter-ions well known in the art and include. Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1 ,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic, glucoheptonic, 3phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid and the like acids; or (2) salts formed when an acidic proton présent in the parent compound either (a) is replaced by a métal ion, e.g., an alkali métal ion, an alkaline earth ion or an aluminum ion, or alkali métal or alkaline earth métal hydroxides, such as sodium, potassium, calcium, magnésium, aluminum, lithium, zinc, and barium hydroxide, ammonia or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, omithine, choline, Ν,Ν'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N- methylglucamine piperazine, tris(hydroxymethyl)aminomethane, tétraméthylammonium hydroxide, and the like. Pharmaceutically acceptable salts further include, by way of example only, sodium, potassium, calcium, magnésium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic fùnctionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, besylate, acetate, maleate, oxalate and the like.
Routes of Administration
The pharmaceutical formulations described herein can be administered via oral-mucosal delivery. In an embodiment, the pharmaceutical formulations described herein are administered to a subject in need thereof in the form of an oral mucoadhesive film. In some embodiments, the pharmaceutical formulations described herein are administered to a subject by placing the oral mucoadhesive film on the tongue of the subject. In some embodiments, the pharmaceutical formulations described herein are administered to a subject by placing the oral mucoadhesive film beneath the tongue of the subject. In some embodiments, the pharmaceutical formulations described herein are administered to a subject by placing the oral mucoadhesive film on the inside of the oral cavity of the subject, such as the left cheek, right cheek, hard palate, soft palate or any combination thereof.
Methods of Treatment
In one aspect, the disclosure provides a method of treating a mucosal disease in a patient in need thereof, the method comprising administering to the subject a pharmaceutical formulation comprising an effect amount of isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive polymer, to thereby treat the disease.
In an embodiment, the mucosal disease is an oral premalignant lésion. In some embodiments, the oral premalignant lésion is oral leukoplakia or oral erythroplakia.
In one aspect, provided herein is a method of treating an oral premalignant lésion in a patient in need thereof comprising mucosally applying any of the films or compositions of any one of the provided herein to the patient, thereby administering an effective amount of the isotretinoin to the patient. In some embodiments, the oral premalignant lésion is oral leukoplakia or oral erythroplakia.
In some embodiments, mucosally applying comprises applying the mucoadhesive layer to the lésion on a mucosa of the mouth of the patient. In some embodiments, one or more lésions are treated comprising applying one or more films or compositions.
Contemplated methods may include administering a disclosed formulation once per week, twice per week, three times per week, four times per week, five times per week, six times per week, once a day, twice a day, three times a day, four times a day, or five times a day. In some embodiments, a formulation may be administered once per day. In some embodiments, a formulation may be administered for about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes. In some embodiments, a treatment regimen comprises mucosally applying any of the films or compositions of any one of the provided herein to the patient once per day for a period of 1 day, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days, 1 month, 2 months 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years. In some embodiments, a treatment regimen comprises mucosally applying any of the films or compositions of any one of the provided herein to the patient once per day for the duration of the patient’s life span. In some embodiments, a treatment regimen comprises mucosally applying any of the films or compositions of any one of the provided herein to the patient once per day until the oral premalignant lésion is resolved.
In one aspect, provided herein is a method of treating an oral premalignant lésion in a patient in need thereof comprising mucosally applying an orally adhesive film comprising about 0.1 to about 0.3 w/w or more of isotretinoin to the oral premalignant lésion for about 30 minutes once daily. It is understood that if a patient has more than one oral premalignant lésion, more than one film may be applied e.g., to each lésion.
In an embodiment, the size and shape of any one of the pharmaceutical formulations disclosed herein to be administered to a patient in need thereof is dépendent on the size and shape of the oral premalignant lésion. In some embodiments, the size and shape of any one of the pharmaceutical formulations disclosed herein to be administered to a patient in need thereof is determined by a medically qualified professional (e.g., a doctor) treating the patient. In some embodiments, the size and shape of any one of the pharmaceutical formulations described herein is modified prior to administering the pharmaceutical formulation to a patient in need thereof. In some embodiments, the size and shape of any one of the pharmaceutical formulations described herein is modified by the medically qualified professional (e.g., a doctor) treating the patient.
Kits
In one aspect, the disclosure provides a kit for the treatment of a mucosal disease, comprising isotretinoin or a pharmaceutically acceptable sait thereof, and a mucoadhesive polymer. In an embodiment, a kit for the treatment of a mucosal disease comprising the formulation disclosed herein, is provided.
In one aspect, provided herein is a kit for suitable storage of an isotretinoin oral film. In some embodiments, the kit comprises a multilayered laminated pouch suitable for packaging any of the mucosal adhesive pharmaceutical films or pharmaceutical formulations provided herein and any of the mucosal adhesive pharmaceutical films or pharmaceutical formulations provided herein. In some embodiments, the multilayered laminated pouch comprises polyester and polyethylene film laminate. In some embodiments, the multilayered laminated pouch further comprises aluminum.
Provided herein, in an embodiment, is a product including a disclosed formulation contained in a kit. Contemplated kits may include a container. In some embodiments, the kit comprises a primary container and a secondary container. In some embodiments, the primary container is the multilayered laminated pouch provided herein. In some embodiments, the multilayered laminated pouch is sealed. In some embodiments, the multilayered laminated pouch comprises a single dose of a pharmaceutical formulation disclosed herein. In some embodiments, the single dose of a pharmaceutical formulation is a mucosal adhesive pharmaceutical film. In some embodiments, the secondary container is a box. In some embodiments, a box contains about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 100 pouched mucosal adhesive pharmaceutical films. In some aspects, contemplated kits may comprise instructions for use in treating a mucosal disease, e.g., a mucosal disease described herein and/or provide instructions for storage, e.g., instructions to store between 15 °C to 30 °C.
EXAMPLES
EXAMPLE 1. Drug dissolution testing protocols
The purpose of this study was to develop a drug dissolution (drug release) method for isotretinoin oral mucoadhesive films. The criterion to achieve was that, at the end of dissolution, the dissolution rate was more than 85%.
The dissolution equipment used was Logan DIS S Ο III-7 (USP 3 and 7 Dissolution Apparatus in one unit), manufactured by Logan Instruments, Somerset, NJ. Program was set to run the test as USP 3 Apparatus. Sampling was done with Logan DSC-37 System Controller/ Logan SYP-8L Syringe Pump and Logan SCR-160 Sampler Collector.
Drug assay of dissolution media was determined by Agilent HPLC/UV System equipped with ChemStation using an in-house method. Medium for the dissolution study was
N,N-Dimethyldodecylamine-N-oxide (DDAO) aqueous solution, 1% (w/w), prepared from 30% DDAO solution, as supplied by Sigma-Aldrich. Other operational parameters were: one film (1 inch x 1 inch) in a cell, medium volume = 200 mL, medium température = 37 °C, reciprocal speed = 20 rpm, and stroke length = 10 cm. Sampling times were 3, 6, 10, 20, 40 and 60 minutes.
Three film formulations were evaluated: 0.1% w/w, 0.2% w/w, and 0.3% w/w isotretinoin. Six cells (n = 6) were used for each formulation.
EXAMPLE 2. Mucoadhesive formulation A
Formulation A for orally dissolvable and erodible thin flexible films with and without a soft (EVA polymer) backing film were formulated. This formulation was designed for slow release of the drug.
Table 1. 0.2% Oral mucosal patch formulation
Ingrédient | Manufacturer | Function | wet g | dry g | dry % |
Purified Water | solvent | 42 | |||
HPMC E5 (CAS RN 25322-68-3) | JRS Pharma | film matrix | 10.7 | 10.7 | 37.7% |
Propylene Glycol | Dow Chemical | plasticizer | 8.2 | 8.2 | 28.9% |
PEG 400 | Dow Chemical | plasticizer | 4.9 | 4.9 | 17.3% |
Acetone | solvent | 24 | |||
Ethanol | solvent | 26 | |||
Noveon AAI | Lubrizol | mucoadhesive | 4.5 | 4.5 | 15.9% |
BHT | Spectrum | antioxidant | 0.03 | 0.0 | 0.1% |
Isotretinoin | active ingrédient | 0.06 | 0.1 | 0.21% | |
Total | 120.39 | 28.4 | 100.00% |
Ail components were dissolved or dispersed in an acetone/ethanol/water (n/n/n ratio of 24/26/42) mixed solvent, and cast directly on EVA polymer backing film, or release liner, and dried at 75 °C for 15 min to produce dry films. For oral dise with the backing film, the casted/dried film is peeled off from the release liner to obtain a stand-alone film. These films are die-cut into 1 inch x 1 inch unit dose dises, and tested accordingly.
In vitro drug release studies were conducted using formulation A and using the drug dissolution protocol described in Example 1. The results of the studies indicated that there was complété release of the drug within approximately 60 minutes.
Drug absorption studies were conducted on cultured human oral mucosal (buccal) tissues supplied by SkinAxis. The drug retained on the tissues after 24 hours was about 2.5 pg/cm .
Three-month accelerated stability studies of formulation A showed that formulation A was stable for 3 months at 25 °C/60% RH and for 1 month at 40 °C/75% RH. The stability study was carried out in accordance with ICH stability testing requirements using Guideline ICH Q1A (R2) and ICH Q1E Evaluation of Stability Data.
EXAMPLE 3. Mucoadhesive formulation B
Mucoadhesive formulation B was formulated to shorten the drug release time in the oral cavity and replace the non-ingestible EVA film with a dissolvable or ingestible backing film. The bioadhesive polymer of formulation A (i.e. Noveon AAI (Polycarbophil)) was replaced with more water-soluble, polyvinylpyrollidone (PVP)-based polymers. Formulation B comprises two layers: the mucoadhesive layer and an ingestible layer formulated with a polymethacrylate (Eudragit)-based polymer (Evonik), which is commonly used as a tablet film coating for oral solid formulations. The two-layer configuration was prepared by two-casting processes.
Table 2. 0.3% isotretinoin formulation for quick-release
Ingrédient | Wet grams | Dry Parts | Dry % |
Water | 4 | ||
Ethanol | 35 | ||
Kollidon 90F | 8 | 8 | 68.1% |
Kollidon VA64 | 2 | 2 | 17.0% |
Isotretinoin | 0.04 | 0.04 | 0.3% |
PEG 400 | 1.5 | 1.5 | 12.8% |
Propylene Glycol | 0.2 | 0.2 | 1.7% |
Total | 50.74 | 11.74 | 100.0% |
Formulation B was prepared using the following procedure. In a 150 mL beaker, water, éthanol, PEG 400, and propylene glycol were added. While the mixture was being stirred, Kollidon VA 64 was added and then Kollidon 90F was added. The mixture was stirred for 10 minutes. Isotretinoin was added while the mixture was being stirred. The mixture was stirred until complété dissolution of ail the solid components had occurred.
The wet solution was then cast onto an ingestible backing film using a wet thickness of about 50 mils (i.e. 1 mil is l/1000th inch) of casting solution (see Table 3).
The casted wet film was then dried at 75 °C for 15 min and die-cut into 1 inch x 1 inch 10 unit dose dises, and tested accordingly.
Table 3. Ingestible Backing Film
Ingrédient | actual, g | Dry g | Dry % |
Ethanol | 43.00 | ||
Water | 10.00 | ||
Eudragit L100-55 | 11.44 | 11.440 | 45.40% |
Eudragit RL PO | 7.36 | 7.360 | 29.21% |
Titanium dioxide | 1.00 | 1.000 | 3.97% |
5404 FD&C Red No.40 | Tiny | ||
PEG400 | 4.21 | 4.000 | 15.87% |
Propylene glycol | 1.80 | 1.400 | 5.56% |
Total | 78.81 | 25.20 | 100% |
The ingestible backing film was prepared by the following procedure. Ethanol, water, propylene glycol and PEG were added into a 150-mL beaker. Titanium dioxide and 5404 FD&C
Red No. 40 were then added to the mixture during stirring. Eudragit polymer was then slowly added to the mixture while the mixture was being stirred. The mixture was stirred for 40 minutes until complété dissolution of the solid components had occurred. The wet solution (thickness of mils) was coated on a polymer based release liner, (Loparex) release side, and was air-dried ovemight. Later on, the wet solution containing the drug would be over-coated on this dried ingestible backing film.
In vitro drug release studies were conducted using the drug dissolution protocol described in Example 1 and the results indicated that complété release of the drug occurred within about 15-20 minutes, as shown in Figure 1.
EXAMPLE 4. Mucoadhesive formulation C
Mucoadhesive formulation C is a quick-dissolving oral film prepared with a highly water-soluble polymer, polyethylene oxide (PEO, low molecular weight) as a film matrix polymer. Low molecular weight PEO polymer is PolyOx N-10 (molecular weight about 100,000), manufactured by Dow Chemical. The composition of fonnulation by ingrédient and the function of each ingrédient is described in Table 4.
Table 4. 0.3% isotretinoin formulation C for quick-release
Ingrédient Name | Function | wet g | dry g | dry % |
Isotretinoin | Active Ingrédient | 0.09 | 0.09 | 0.30% |
PolyOx N10 | Film matrix polymer | 21.0 | 21 | 70.61% |
Propylene Glycol | Film Plasticizer | 4.0 | 4 | 13.45% |
PEG 600 | Film Plasticizer | 3.5 | 3.5 | 11.77% |
Aspartame | Sweetener | 0.5 | 0.5 | 1.68% |
Peppermint Oil | Flavoring Agent | 0.5 | 0.5 | 1.68% |
BHT | Antioxidant | 0.15 | 0.15 | 0.50% |
Ethanol | Solvent | 15 | ||
Water | Solvent | 50 | ||
total | 94.74 | 29.74 | 100% |
Propylene glycol, PEG 600, Peppermint Oil, water, and éthanol were added to a 100 mL beaker and stirred for five minutes. The PolyOx N10 was then gradually added into the beaker and stirring continued until complété dissolution of the PolyOx NI 0 had occurred. The BHT, aspartame and isotretinoin were then added to the solution and stirred until complété dissolution occurred.
Using a casting (draw-down) applicator, a wet thin film (30 mil thick) was cast (coat) onto a polyester release liner (e.g., 3M’s Scotchpak 9744). The wet film was then dried in a forced-air oven at 90 °C for 10 min. After removing the dried film from the oven, the supporting release liner was discarded, and the neat oral film was then die-cut into a final unit dosage form (one inch by one inch oral) mucoadhesive film. Each unit was found to weigh about 100 mg and contained 0.3% of isotretinoin. In certain instances, the unit-dose film was contained in a sealed multi-laminated foil pouch.
The unit dose was tested to détermine the dissolution rate of isotretinoin using the drug dissolution protocol described in Example 1. Total dissolution in water was found to occur in 10 about two minutes.
EXAMPLE 5. Mucoadhesive formulation D
Mucoadhesive formulation D is a quick-dissolving oral film prepared using a highly water-soluble, film forming polymer, hydroxyl methyl propyl cellulose (HPMC) as a film matrix 15 polymer. The HPMC polymer used was Methocel E5, manufactured by Dow Chemical. The composition of formulation by ingrédient and the function of each ingrédient is described in Table 5.
Table 5. 0.3% isotretinoin formulation D for quick-release
Function | wet g | dry g | dry % | |
Methocel E5 | Film matrix polymer | 21 | 21 | 70.4% |
Isotretinoin | Active ingrédient | 0.09 | 0.09 | 0.30% |
Propylene Glycol | Film plasticizer | 3.5 | 3.5 | 11.7% |
PEG-400 | Film plasticizer | 3.5 | 3.5 | 11.7% |
Aspartame | Sweetener | 0.5 | 0.5 | 1.7% |
Peppermint Oil | Flavor | 0.5 | 0.5 | 1.7% |
BHT | Antioxidant | 0.15 | 0.15 | 0.5% |
Kolliphor EL | Solubilizer | 0.6 | 0.6 | 2.0% |
Ethanol | Solvent | 20 | ||
Water | Solvent | 50 | ||
total | 99.84 | 29.84 | 100% |
Propylene glycol, PEG 400, Peppermint Oil, Kolliphor EL (also known as Cremphor EL), water, and éthanol were added to a 200 mL beaker and stirred for five minutes. The Methocol E5 was then gradually added into the beaker and stirring continued until complété dissolution of the Methocol E5 had occurred. The BHT, aspartame and isotretinoin were then added to the solution and stirred until complété dissolution occurred.
Using a casting applicator, a wet thin film (30 mil thick) was cast (coat) onto a polyester release liner. The wet film was then dried in a forced-air oven at 90 °C for 10 min, to remove the solvents. After removing the dried film from the oven, the supporting release liner was discarded and the film was then die-cut into a final unit dosage form (one inch by one inch oral) mucoadhesive film. Each unit was found to weigh about 100 mg and contained 0.3% of isotretinoin. In certain instances, the unit-dose film was contained in a sealed multi-laminated foil pouch.
The unit dose was tested to détermine the dissolution rate of isotretinoin using the drug dissolution protocol described in Example L Total dissolution in water was found to occur in about five minutes.
EXAMPLE 6. Mucoadhesive formulation E
This example demonstrates that oral films of isotretinoin with higher mucoadhesion and slower drug release properties were prepared using a combination of two water-swellable polymers, Carbopol (polyacrylic acid, supplied by Lubrizol) and xantham gum. Carbopol provides strong adhesion with the oral mucosal tissues, through ionic interactions, when wetted with saliva. The composition of formulation by ingrédient and the function of each ingrédient is described in Table 6.
Table 6. 0.3% isotretinoin formulation E for sustained-release
Ingrédient | Function | wet g | dry g | dry % |
Propylene Glycol | Film Plasticizer | 8 | 8.0 | 34.4% |
PEG 400 | Film Plasticizer | 5 | 5.0 | 21.5% |
Acetone | Solvent | 24 | ||
Ethanol | Solvent | 29 | ||
Xantham Gum | Matrix Polymer/Bio-adhesive | 5.4 | 5.4 | 23.2% |
Carbopol 971 | Matrix Polymer/Bio-adhesive | 4.8 | 4.8 | 20.6% |
Isotretinoin | Active ingrédient | 0.07 | 0.07 | 0.30% |
BHT | Antioxidant | 0.12 | 0.12 | 0.52% |
Total | 76.27 | 23.3 | 100.00% |
Propylene glycol, PEG 400, acetone, and éthanol were added to a 200 mL beaker and stirred for five minutes. The xantham gum was then gradually added into the beaker and stirring continued until complété dissolution occurred. In the same manner, the Carbopol 971 was added to the solution. The BHT and isotretinoin were then added to the solution and stirred until complété dissolution occurred.
Using a casting applicator, a wet thin film (40 mil thick) was cast (coat) onto a polyester release liner. The wet film was then dried in a forced-air oven at 90 °C for 10 min, to remove the solvents. After removing the dried film from the oven, the supporting release liner was discarded and the film was then die-cut into a final unit dosage form (one inch by one inch oral) mucoadhesive film. Each unit was found to weigh about 100 mg and contained 0.3% of isotretinoin. The films exhibited high elasticity and good muco-adhesion. In certain instances, the unit-dose film was contained in a sealed multi-laminated foil pouch.
The unit dose was tested to détermine the dissolution rate of isotretinoin using the drug dissolution protocol described in Example 1. Total dissolution in water was found to occur in about 2 hours indicating sustained release of the drug.
EXAMPLE 7. Mucoadhesive formulation F
This example demonstrates that oral films of isotretinoin with higher mucoadhesion and slower drug release properties were prepared using medium molecular weight (300,000) polyethylene oxide (PEO), PolyOx N-750 (manufactured by Dow Chemical). Films prepared from medium to high MW PolyOx polymers are known to provide strong adhesion with the oral mucosal tissues when wetted with saliva. The composition of formulation by ingrédient and the function of each ingrédient is described in Table 7.
Table 7. 0.3% isotretinoin formulation E for sustained-release
Ingrédient | Function | Wet grams | Dry grams | Dry % |
Water | Solvent | 4 | ||
Ethanol | Solvent | 30 | ||
PolyOx N-750 | Matrix polymer/bio-adhesive | 10 | 10 | 75.8% |
PEG 400 | Film plasticizer | 2 | 2 | 15.2% |
Propylene Glycol | Film plasticizer | 1.2 | 1.2 | 9.1% |
Isotretinoin | Active ingrédient | 0.04 | 0.04 | 0.30% |
BHT | Antioxidant | 0.07 | 0.07 | 0.53% |
Total | 47.2 | 13.2 | 100% |
Propylene glycol, PEG 400, water, and éthanol were added to a 200 mL beaker and stirred for five minutes. The PolyOx N-750 was then gradually added into the beaker and stirring continued until complété dissolution occurred. The BHT and isotretinoin were then added to the solution and stirred until complété dissolution occurred.
Using a casting applicator, a wet thin film (40 mil thick) was cast (coat) onto a polyester release liner. The wet film was then dried in a forced-air oven at 90 °C for 10 min, to remove the solvents. After removing the dried film from the oven, the supporting release liner was discarded and the film was then die-cut into a final unit dosage form (one inch by one inch oral) mucoadhesive film. Each unit was found to weigh about 100 mg and contained 0.3% of isotretinoin. In certain instances, the unit-dose film was contained in a sealed multi-laminated foil pouch.
The unit dose was tested to déterminé the dissolution rate of isotretinoin using the drug dissolution protocol described in Example 1. Total dissolution in water was found to occur in about 1 hour.
EXAMPLE 8. Mucoadhesive formulations G, H, I and J
Isotretinoin oral film formulations with various types of antioxidants were prepared, using the method and composition (except antioxidant or no antioxidant) based on Example C. Table 8 below summarizes the type and quantity of antioxidant used.
Table 8. Isotretinoin formulations comprising various antioxidants
Antioxidant | Formulation C | Formulation G | Formulation H | Formulation I | Formulation J |
BHT | 0.50% | no antioxidant | |||
Vitamin E | 0.50% | ||||
ascorbyl palmitate | 0.50% | ||||
propyl gallate | 0.50% |
The isotretinoin oral film formulations (formulation C, and formulations G to J) were packaged in multi-laminate foil pouches and subjected to a Chemical stability study at 60 °C. They were stored in an oven at 60 °C for two weeks, removed and assayed for drug content and possible dégradants using a HPLC method. The test results showed that after 10 days at 60 °C, samples of formulation J showed significant dégradation (e.g., dégradants were detected by HPLC), while formulations C, G, H, and I did not show any dégradation. The tests showed that isotretinoin oral films formulated with 0.5% of BHT, vitamin E, ascrobyl palmitate, or propyl gallate were effective in enhancing the Chemical stability of the isotretinoin (e.g., prevent it from oxidation). The stability study was carried out in accordance with ICH stability testing requirements using Guideline ICH Q1A (R2) and ICH Q1E Evaluation of Stability Data.
EXAMPLE 9. Mucoadhesive formulations K, L, M and N
Formulation K is a dual-layer thin oral adhesive film containing isotretinoin intended for application to oral mucosal tissues. The oral adhesive film (1 inch by 1 inch in size) has two layers: the drug-containing mucosal adhesive layer and a customer-formulated ingestible layer formulated with a polymethacrylate (Eudragit®)-based polymer, which is commonly used as a tablet film coating for oral solid dosage forms. The ingestible film serves as an occlusive backing to achieve one-directional drug release/absorption/mucosal perméation.
The composition of formulations K, L, M and N (0% w/w, 0.1% w/w, 0.2% w/w and 0.3% w/w isotretinoin) comprising a drug layer and a backing layer is given below in Table 9 and Table 10, respectively.
Table 9. Composition of the drug layer for formulations K, L, M and N (unit)
Ingrédient | Function | % per formulation K | % per formulation L | % per formulation M | % per formulation N |
Kollidon 90F | Film matrix polymer | 56.10 | 56.05 | 55.99 | 55.94 |
Kollidon VA64 | Film matrix polymer | 14.03 | 14.0 | 14.00 | 13.98 |
Isotretinoin | Active Ingrédient | 0.0 | 0.10 | 0.20 | 0.30 |
Titanium dioxide | Opacity agent | 4.49 | 4.48 | 4.48 | 4.47 |
FD&C Yellow #6 | Colorant | 0.09 | 0.09 | 0.09 | 0.09 |
Nat Mint | Flavor | 2.38 | 2.38 | 2.38 | 2.38 |
BHT | Antioxidant | 0.46 | 0.46 | 0.46 | 0.46 |
PEG 400 | Plasticizer | 17.53 | 17.52 | 17.50 | 17.48 |
Propylene Glycol | Plasticizer | 4.91 | 4.90 | 4.90 | 4.89 |
Table 10. Composition of the non-drug (backing) layer for ail formulations (unit)
Ingrédient | Function | % per film |
Eudragit Ll00-55 | Polymer | 43.66% |
Eudragit RL PO | Polymer | 27.71% |
Titanium Dioxide | Opacity Agent | 7.59% |
FD&C Red No.40 | Colorant | 0.53% |
PEG400 | Plasticizer | 15.19% |
Propylene glycol | Plasticizer | 5.32% |
The stability of formulations L, M and N was carried out according to ICH stability testing requirements using Guideline ICH Q1A (R2) and ICH Q1E Evaluation of Stability Data.
Formulations L, M and N were stored in sealed foil laminate pouches, as disclosed herein, under storage conditions of 25 °C/60% RH and 40 °C/75% RH. Samples of the different 5 formulations were removed from storage at 0, 1, 2, 3 and 6 months and assayed for drug content and possible dégradants using a HPLC method. The acceptance criteria used in the stability study were: (1) a moisture content of not more than 7.5% (w/w), (2) drug content between 90 - 110% of original drug content, (3) individual dégradant content not more than 0.5% (w/w) and (4) total dégradant content no more than 3% (w/w).
Formulations L, M and N were ail found to be stable at both 25 °C/60% RH and 40 °C/75% RH for up to 6 months.
EXAMPLE 10. Protocol for Perméation Experiments Using Cultured Tissues
Receiver fluid was prepared according to the following procedure. The assay medium is pre-warmed to 37 °C. Phosphate buffer solution (PBS) of pH 6.8 is used for oral cavity tissues.
Phosphate buffer solution of pH 7.4 is used for cultured skin. The medium is pipetted into each well of the plates. The volume of the added medium should be just enough to cover the tissue membrane (0.3 to 0.5 mL, depending on whether they are 6-well, 12-well, or 24-well plates). The plates are labeled to accommodate sampling at desired time points. For example, the wells are labeled as 0.5, 1.0, 1.5, 2.0, and 2.5 hours. This method involves moving the tissues from well to well at the appropriate time point. An alternative method is to remove ail receiver solution at the appropriate time point (receiver solution is saved for later analysis) and refïll the well with fresh receiver solution.
0.5 mL of donor solution is used on the donor well or appropriate matching sized patch or film. The articles should be in good contact with the tissue surfaces.
The permeability experiment was conducted according to the following procedure. The donor solution was pipetted onto the tissue or the die-cut patch or film was placed onto the tissue. The plates were retumed to the incubator. After the first elapsed perméation time, the tissues were moved to the next wells. The receiver media in HPLC vials were collected and kept in the refrigerator. The tissues were moved after the next few time-points of total elapsed time.
EXAMPLE 11. Mucosal Tissue Permeation/Deposition Kinetic Study
An in vitro mucosal tissue permeation/deposition kinetic study was conducted with the 0.1%, 0.2%, and 0.3% isotretinoin oral adhesive film formulations of Example 9. Two 6-well plates were provided with each well containing a 1-inch tissue. One 1-inch diameter film was placed on the oral mucosal tissue. The permeated and deposited amounts of isotretinoin were determined at Day 1, 2 and 3 using éthanol extraction procedure, and the concentrations were assayed by HPLC. Results are provided in Table 11. Each value reported is the average of 3 cell measurements. The préparation of the cultured tissues used in the kinetic study is described in Example 10.
Table 11. Results from In Vitro Mucosal Tissue Permeation/Deposition Kinetic Study
Day | Drug Déposition in Skin, pg/cm2 | |||
0.1% isotretinoin formulation | 0.2% isotretinoin formulation | 0.2% isotretinoin formulation | 0.3% isotretinoin formulation | |
1 | 2.63 | 3.83 | nd | 3.39 |
2 | 3.05 | 4.08 | nd | 4.09 |
3 | 3.32 | 4.30 | 3.98 | 3.75 |
This in vitro study of oral mucosal tissue suggests that isotretinoin can be more highly concentrated in the tissue if a 0.3% film is administered directly to the oral lésion, with an average mucosal tissue concentration of 3.75 pg/cm2, but minimal pénétration outside the tissue.
EXAMPLE 12. In Vitro Cytotoxicity and Irritation Testing of CCP-042 on Oral Epithelial Cells
For this study, three patches of CCP-042 oral adhesive film (0.1%, 0.2%, and 0.3%) were used. Untreated samples were tested in parallel as négative Controls.
Evaluation of cytotoxicity in 2D cultured oral épithélial cells
Human gingival kératinocytes derived from a single donor were cultured at 37 °C with 5% CO2, and 95% humidity in a 96-well plate for cytotoxicity évaluation. Cells were incubated in the presence of seven concentrations of isotretinoin ranging from 0.3 to 0.00003% for 24 h in triplicate. Untreated cells were used as baseline control. Cytotoxicity was evaluated using the Cell Titer96 Aqueous One (Promega, WI, USA) basic test according to manufacturer’s instructions using an absorbance of 490 nm for the final colorimétrie readings. The concentration of isotretinoin showing the inhibition of viability of more than 20% of the control values was considered cytotoxic. At ail tested concentrations, isotretinoin was toxic to gingival cells (Figure 1).
Skin irritation testing of isotretinoin formulations in 3D cultured oral épithélial cells
Human oral mucosa 3D models (composed of human gingival kératinocytes) were exposed topically to CCP-042 oral adhesive film (0.1%, 0.2%, and 0.3%) for 4 hr before viability assessment. Cell viability was measured by MTT assay on tissues, in triplicate. 1% Triton X-100 was used as positive control. The réduction of the viability of tissues exposed to formulations as compared to that of PBS-treated négative Controls were used to predict the skin irritation potential using European Union (EU) and Globally Harmonized System (GHS) classifications, which define an irritant as a substance that reduces the viability of the exposed tissue to less than 50% of the viability of untreated Controls.
Significant changes were observed at ail the tested isotretinoin concentrations relative to the untreated tissues. However, with respect to the vehicle control, only the highest tested formulation (0.3%) decreased tissue viability, thus suggesting that isotretinoin is not toxic at concentrations of 0.1% and 0.2%.
EXAMPLE 13. Acute Oral Irritation in Hamster Cheek Model
A non-GLP irritation study was conducted in Golden Syrian hamsters to evaluate local tolérance and acute toxicity associated with two daily applications of three dose strengths of CCP-042 (0.1, 0.2, and 0.3%) compared to a placebo (vehicle control) followed by a 3-day recovery period.
Twenty-four (24) young adult hamsters (12 males and 12 females) were used in this study. CCP- 042 oral adhesive films were administered by applying the drug-side of the film to the left buccal mucosa of the cheek pouch and allowing it to dissolve. The clean everted pouch was examined and scored according to the modified Draize “Scale for Scoring Oral Mucosa”. The right cheek received no treatment. Drinking water was withheld from the animais 1 hour before the first dose and until 2 hours after the second dose. The second dose was administered 4 hours after the first dose. Safety and local tolerability were assessed by monitoring signs of toxicity before each dosing interval, twice per day on the day of dosing and once per day for the 3 days of recovery (total of 4 days). Any adverse effect of the test articles was assessed by behavioral response of the animais. Abnormal findings were recorded. Ail animais were observed at least twice daily for sign of viability. Scoring for buccal mucosal was performed 3 times daily throughout the dosing period. Scoring for buccal mucosal irritation continued at 24, 48 and 72 hours following the final dose to assess reversibility. After the pouch was rinsed and clear of food particles and while it was everted, observations were made and recorded by scalar notation from “0” to “4”. Results are provided below. Buccal mucosa irritation average score was calculated using the group erythema scores and the group edema scores and determined the average for each group and sex at each time period.
Twenty-four animais (twelve males and twelve females) were randomly assigned to each of the following test groups (Table 12):
Table 12. Group Average Mucosal Irritation Scores in Hamster Cheek Tolerability Study
Time Postapplication (h) | Buccal Mucosal Irritation Average Score | |||
Vehicle Control (0 %) | Low Dose (0.1%) | Mid Dose (0.2%) | High Dose (0.3%) | |
1 ( 1 st dose) | 0 | 0.15 | 0.25 | 0.35 |
5 (2nd dose) | 0 | 0.15 | 0.45 | 0.5 |
24 | 0 | 0 | 0.25 | 0.35 |
48 | 0 | 0 | 0.25 | 0.1 |
72 | 0 | 0 | 0.35 | 0 |
The Group 2 (0.1% dose - low dose) Average Erythema Score ranged from 0 to 0.3; Average Edema Score was 0; and Average Mucosal Irritation Score ranged from 0 to 0.15 indicating that the test article was not considered an irritant at this dose.
The Group 3 (0.2% dose - mid dose) Average Erythema Score ranged from 0.2 to 0.7;
Average Edema Score ranged from 0 to 0.5; and Average Mucosal Irritation Score ranged from 0.25 to 0.45. Scores observed at 48 and 72 hours were attributed to observations recorded for animal 3815 interpreted to be due to mechanical injury during dosing, therefore the test article was not considered an irritant at this dose.
The Group 4 (0.3% dose - high dose) Average Erythema Score ranged from 0 to 0.8;
Average Edema Score ranged from 0 to 0.2; and Average Mucosal Irritation Score ranged from 0 to 0.50, with complété resolution of both edema and erythema at 72 hours after test article administration, therefore the test article was not considered an irritant at this dose level.
There were no mortalities during the study. Slight swelling of the face observed in one male in the Group 3 was attributed to the dosing procedure related mechanical injury and not 15 considered a test article effect.
Following the last day’s observation (Day 4), ail animais were euthanized and the right and left cheek pouch from ail animais were examined microscopically. Evaluation of the oral mucosa of the cheek pouch included, but not limited to, evidence of edema, inflammatory cell infiltrâtes or inflammation, épithélial and vascular changes. There was no evidence of test substance-related irritation of the oral mucosa of the cheek pouch.
Under the conditions of this study, the application of CCP-042 films at the doses up to 0.3% in male and female Golden Syrian hamsters did not produce buccal mucosal irritation.
EXAMPLE 14. Drug release study for mucoadhesive formulations L, M and N
Drug dissolution profiles of isotretinoin oral mucoadhesive films comprising formulations L, M, and N (Example 9) were carried out using the drug dissolution protocols described in Example 1.
The drug release data (%), averaged values (AVE), along with standard déviation 5 (STD) and % RSD, for the three formulations tested at the pre-selected sampling times are given in Table 13.
Table 13. Drug release data for Formulations L, M and N
Time (min) | Formulation L | Formulation M | Formulation N | ||||||
AVE drug released | STD | %RSD | AVE drug released | STD | %RSD | AVE drug released | STD | %RSD | |
0 | 0.0 | n/a | n/a | 0.0 | n/a | n/a | 0.0 | n/a | n/a |
3 | 27.5% | 7.3% | 26.7% | 21.3% | 5.8% | 27.1% | 25.2% | 12.7% | 50.6% |
6 | 84.4% | 3.3% | 3.9% | 78.9% | 4.4% | 5.6% | 76.2% | 6.0% | 7.9% |
10 | 95.2% | 2.8% | 3.0% | 91.7% | 6.1% | 6.6% | 86.2% | 6.3% | 7.4% |
20 | 96.3% | 2.6% | 2.7% | 95.6% | 7.6% | 8.0% | 93.7% | 6.1% | 6.5% |
40 | 96.5% | 2.6% | 2.7% | 95.6% | 8.1% | 8.5% | 94.9% | 5.4% | 5.7% |
60 | 96.3% | 2.2% | 2.3% | 95.8% | 7.9% | 8.3% | 95.9% | 5.5% | 5.8% |
Plots of drug dissolution profiles for Formulations L, M, and N are given in Figure 4.
Ail 3 formulations meet criterion of more than 85% drug release by end of dissolution (60 minutes). %RSD appears to be acceptable for ail 3 formulations. Clear discriminations of drug dissolution profiles were showed among the 3 formulations of 0.1, 0.2, and 0.3% isotretinoin formulations.
EQUIVALENTS
The disclosure can be embodied in other spécifie forms with departing from the essential characteristics thereof. The foregoing embodiments therefore are to be considered illustrative rather than limiting on the disclosure described herein. The scope of the disclosure is indicated by the appended claims rather than by the foregoing description, and ail changes that corne within the meaning and range of equivalency of the claims are intended to be embraced therein.
What is claimed:
Claims (10)
1. An oral adhesive pharmaceutical film comprising:
a mucoadhesive layer comprising about 0.1% w/w to about 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 11% w/w to about 18% w/w vinylpyrrolidonevinyl acetate co-polymer and about 50% to about 60% w/w polyvinylpyrrolidone (PVP); and an occlusive ingestible backing layer, wherein the film provides substantially one-directional release of the isotretinoin, and wherein using a USP 3 or USP 7 dissolution apparatus, at least 85% of the isotretinoin in the mucoadhesive layer is released after 20 minutes.
2. The oral adhesive pharmaceutical film of claim 1, wherein the PVP has a weight average molecular weight of about 70,000 g/mol to about 1,600,000 g/mol.
3. The oral adhesive pharmaceutical film of claim 1, wherein the vinylpyrrolidone-vinyl acetate co-polymer has a weight average molecular weight of about 45,000 g/mol to about 70,000 g/mol.
4. The oral adhesive pharmaceutical film of claim 1, wherein the mucoadhesive layer comprises about 0.2% w/w isotretinoin.
5 and an occlusive ingestible backing layer, for use in a method of treatment of an oral premalignant lésion in a patient in need thereof, wherein the oral adhesive pharmaceutical film is applied to the oral premalignant lésion once daily.
5. The oral adhesive pharmaceutical film of claim 1, wherein the occlusive ingestible backing layer comprises a polymer selected from the group consisting of poly(methacrylic acid-coethylacrylate) 1:1, poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2, and combinations thereof.
6. The oral adhesive pharmaceutical film of claim 1, wherein the mucoadhesive layer further comprises propylene glycol (PG) and a polyethylene glycol (PEG).
7. The oral adhesive pharmaceutical film of claim 6, wherein the PEG is PEG 400.
8. An oral mucosal adhesive pharmaceutical film for one directional release comprising:
a mucoadhesive layer comprising about 0.1% w/w to about- 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 12% w/w to about 15% w/w vinylpyrrolidonevinyl acetate copolymer, about 53% w/w to about 57% w/w PVP, about 16% w/w to about 19% w/w PEG 400 and about 4% w/w to about 6% w/w propylene glycol; and an occlusive ingestible backing layer.
9. The oral mucosal adhesive pharmaceutical film of claim 8, wherein the occlusive ingestible backing layer comprises poly(methacrylic acid-co-ethylacrylate) 1:1, poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2, PEG 400 and propylene glycol.
10. The oral adhesive pharmaceutical film of claim 1, wherein the mucoadhesive layer comprises about 0.3% w/w isotretinoin.
11. The oral mucosal adhesive pharmaceutical film of claim 8, wherein the mucoadhesive layer releases 76.2 ± 6% w/w of the isotretinoin after 6 minutes, when tested in 200 mL 1% (w/w) N,N-dimethyldodecylamine-N-oxide aqueous solution in a USP 3 apparatus at 20 rpm.
12. An oral adhesive pharmaceutical film comprising a mucoadhesive layer comprising about 0.2% w/w to about 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 11% w/w to about 18% w/w vinylpyrrolidonevinyl acetate co-polymer and about 50% to about 60% w/w polyvinylpyrrolidone (PVP); and an occlusive ingestible backing layer, for use in a method of treatment of an oral premalignant lésion in a patient in need thereof, wherein the oral adhesive pharmaceutical film is applied to the oral premalignant lésion for about 15 minutes to about 30 minutes once daily thereby administering, by one directional release, an effective amount of the isotretinoin to the patient.
13. The oral adhesive pharmaceutical film for use of claim 12, wherein the oral premalignant lésion is oral leukoplakia or oral erythroplakia.
14. The oral adhesive pharmaceutical film for use of claim 12, wherein the PVP has a weight average molecular weight of about 70,000 g/mol to about 1,600,000 g/mol.
15. The oral adhesive pharmaceutical film for use of claim 12, wherein the vinylpyrrolidonevinyl acetate co-polymer has a weight average molecular weight of about 45,000 g/mol to about 70,000 g/mol.
16. The oral adhesive pharmaceutical film for use of claim 12, wherein the mucoadhesive layer comprises about 0.3% w/w isotretinoin.
17. An oral adhesive pharmaceutical film comprising a mucoadhesive layer comprising about 0.1% w/w to about 0.3% w/w isotretinoin or a pharmaceutically acceptable sait thereof, about 12% w/w to about 15% w/w vinylpyrrolidonevinyl acetate co-polymer, about 53% to about 57% w/w polyvinylpyrrolidone (PVP), about 16% w/w to about 19% w/w PEG 400 and about 4% w/w/ to about 6% w/w propylene glycol;
10 18. The oral adhesive pharmaceutical film for use of claim 17, wherein the occlusive ingestible backing layer comprises poly(methacrylic acid-co-ethylacrylate) 1:1, poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl méthacrylate chloride) 1:2:0.2, and PEG 400.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/526,743 | 2017-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA20027A true OA20027A (en) | 2021-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210244656A1 (en) | Isotretinoin oral-mucosal formulations and methods for using same | |
ES2645449T3 (en) | Topical tetracycline formulations, preparation and uses thereof | |
JP5213446B2 (en) | Pharmaceutical composition comprising diclofenac | |
JP6929916B2 (en) | An electrohydrodynamically obtained pharmaceutical composition containing fibers with improved residence time at the application site. | |
EP4076380B1 (en) | Transmucosal therapeutic system containing agomelatine | |
JP2014516061A (en) | Edible oral strip or wafer dosage form containing ion exchange resin for taste masking | |
Chaturvedi et al. | Fast dissolving films: a review | |
WO2020086673A1 (en) | Ketamine oral transmucosal delivery system | |
JP2013515782A (en) | Orally administrable film formulation containing ondansetron | |
US20090053309A1 (en) | Adhesive compositions for the treatment of xerostomia | |
US20220401389A1 (en) | Transmucosal therapeutic system containing agomelatine | |
JP2019523212A (en) | Fast-acting orally disintegrating film for local anesthetic administration | |
US20230321039A1 (en) | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof | |
OA20027A (en) | Isotretinoin oral-mucosal formulations and methods for using same. | |
EP2919752A1 (en) | Medicinal lozenge based on ibuprofen sodium dihydrate | |
JP2006070027A (en) | Administration agent to mucous membrane in oral cavity | |
WO2016079246A1 (en) | Bioadhesive films | |
MISHRA et al. | An Overview of Buccal Drug Delivery System. | |
ES2547419T3 (en) | Solid compositions containing non-steroidal anti-inflammatory drugs, procedures for their preparation and use | |
WO2024092106A2 (en) | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof | |
TW202310840A (en) | Apixaban film product and uses thereof |